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ABBREVIATIONS 
 
αGalCer – α-galactosylceramide 
AIS – acute ischemic stroke 
APC – antigen presenting cell 
CD – cluster of differentiation 
CDR – complementarity-determining region 
CI  – confidence interval 
CIDP – chronic inflammatory demyelinating polyneuropathy 
CNS – central nervous system 
CTLA-4  – cytotoxic T lymphocyte-associated antigen-4 
DEG – differentially expressed genes 
DN – double negative (CD4-CD8-) 
EAE – experimental autoimmune encephalomyelitis 
FasL – Fas ligand 
GOS – Glasgow Outcome Scale 
HLA  – human leukocyte antigen 
hsCRP – high-sensitivity C-reactive protein 
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ICOS – inducible co-stimulatory molecule  
IFN- γ – interferon-γ 
Ig – immunoglobulin 
IL  – interleukin  
iNKT cells – invariant natural killer T cells 
LAR  – leukocyte antisedimentation rate  
MAIT  – mucosal-associated invariant T cells 
MHC  – major histocompatibility complex 
MS – multiple sclerosis 
NK cells – natural killer cells 
NKT-like cells – natural killer T-like cells 
OR – odds ratio 
PCT – procalcitonin 
RRMS – relapsing-remitting multiple sclerosis 
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SNP – single nucleotide polymorphism 
SSCP – single-strand conformation polymorphism 
TCR – T cell receptor 
Th – T helper  
TIA  – transient ischemic attack 
TNF-α – tumor necrosis factor-α  
UTR – untranslated region 
WHO  – World Health Organization 
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I. INTRODUCTION: 
Basis of experimental work and theses 
 
Immunity 
The term immunity is derived from the Latin word immunitas, which referred to the 
protection from legal prosecution offered to Roman se ators during their tenures in office. 
Historically, immunity meant protection from diseas and, more specifically, infectious 
disease. The major function of the immune system is to recognize invading microbes, infected 
cells and tumors, and efficiently launch attacks that destroy them while ignoring healthy 
tissues – basically to preserve and maintain the body’s integrity. The immune system, 
however, provides defense not only against bacteria, parasites, fungi and viruses that can 
cause infections, but against noninfectious foreign substances, macromolecules, such as 
proteins and polysaccharides, and small chemicals th t are recognized as foreign, and also 
against tumor cells. The immune system consists of special organs, billions of cells, sets and 
subsets, molecules responsible for immunity – all organized into an elaborate and dynamic 
communications network. The immune system is amazingly complex – and so is the nervous 
system [1,2].  
Defense against foreign cells and substances is mediated by the early reactions of 
innate immunity and the later responses of adaptive immunity, the two functional arms of the 
immune system. Innate immunity (also called natural o  native immunity) provides the early, 
rapid, non-specific, first line of defense against microbes and tumor cells and activates the 
adaptive immunity, which provides specific immune responses against pathogens, and bears 
immune memory: the adaptive response that takes day to develop on first encounter with a 
microorganism is effective almost immediately on subsequent infection with the same 
organism. The principal components of innate immunity are physical and chemical barriers, 
such as epithelia and antimicrobial substances produced at epithelial surfaces, neutrophils, 
macrophages, dendritic cells and natural killer (NK) cells, blood proteins, including members 
of the complement system and other mediators of inflammation, acute phase proteins, and 
cytokines that regulate and coordinate many of the activities of the cells of innate immunity 
[3,4].  
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Natural killer (NK) cells and cytotoxicity 
NK cells are crucial components of the innate immune system, which are able to 
rapidly produce abundant cytokines, mainly interferon-gamma (IFN-γ), and lyse target cells 
without prior sensitization through cytotoxicity. NK cells play a key role in resistance to 
infections and destruction of tumor cells. They expr ss CD56 on their surface, which is 
widely used as an NK cell marker to identify them, and lack the expression of antigen-specific 
T cell receptor complex, CD3 [5,6].  
Perforin and Fas/FasL pathways are the two major mechanisms of cellular cytotoxicity 
[7,8]. Exocytosis of cytotoxic granules containing pre-formed perforin and serine esterase 
molecules leads to cell lysis by forming pores in target cell membranes. Perforin is a marker 
of cytotoxic cells [9]. FasL produced by effector cells induces apoptosis through Fas, its 
receptor on target cell surfaces. The Fas/FasL-mediated apoptotic pathway thus depends on 
cell-surface ligand-receptor interaction [10].  
 
T cell receptor (TCR) 
T lymphocytes are one of the major cellular components of the adaptive immune 
system. Lymphocytes are the only cells in the body capable of specifically recognizing and 
distinguishing different antigenic determinants and are responsible for the two defining 
characteristics of the adaptive immune response, specificity and memory mediated by 
antigen-specific receptors.  
T cell receptors comprise an essentially unlimited r pertoire of variants, each variant 
expressed on a different cell, that can altogether recognize virtually any molecule. Versatility 
of T cell receptors and thus of antigen recognition is primarily a result of the rearrangement of 
antigen receptor coding genes. The diversity of the lymphocyte repertoire is further enhanced 
by randomly adding and removing nucleotides during the joining of different gene segments 
and spontaneous mutations also occur. The TCR is a heterodimer consisting of two 
transmembrane polypeptide chains, designated α and β, covalently linked to each other by a 
disulfide bridge. Each α-chain and β-chain consists of one immunoglobulin (Ig)-like N-
terminal variable (V) domain, one Ig-like constant (C) domain, a hydrophobic transmembrane 
region, and a short cytoplasmic region. The V regions f the TCR α and β chains contain short 
stretches of amino acids where the variability betwe n different TCRs is concentrated, and 
these form the hypervariable or complementarity-determining regions (CDRs). Three CDRs 
in the α chain are juxtaposed to three similar regions in the β chain to form the part of the 
TCR that specifically recognizes peptide-MHC complexes. In the α and β chains of the TCR, 
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the third hypervariable regions are composed of sequences encoded by V and J (joining) gene 
segments (in the α chain) or V, D (diversity), and J segments (in the β chain) [1-4] (Figure 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Rearrangement and structure of the T cell receptor 
 
Cytotoxic CD8+, Thelper CD4+ cells, and co-stimulation (CTLA-4) 
T cells with their TCRs recognize MHC (major histocompatibility complex) molecules 
complexed with different (fragments of) antigens. CD8+ cytotoxic T cells recognize peptide 
antigens generated in the cytosol from viruses, or cytosolic bacteria, and presented by MHC 
class I molecules on the surface of infected cells: thi  activates the cytotoxic T cell to kill the 
infected cell, limiting the replication of the infecting agent. MHC class I molecules are 
expressed on almost all cells. CD4+ T helper (Th) cells, which activate other cells of the 
immune system, recognize peptide fragments presented by MHC class II molecules, and are 
thereby activated to secrete cytokines and activate other immune cells, which kill the 
microorganisms or secrete antibodies [1,2].   
The antigen-specific stimulation through the TCR is not enough for the full activation 
of T cells, a second signal called co-stimulation is necessary. Both antigen presenting cells 
(APC) and T cells will be activated during co-stimulation, a sequence of ligand-receptor 
interactions on the surface of both cells. Such interactions are required also for the termination 
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of activation, a mechanism important in autoimmune tol rance. This termination is mainly 
mediated by CTLA-4 (cytotoxic T-lymphocyte-associated antigen-4) expressed on the surface 
of T cells upon activation [3]. Another molecule, called inducible co-stimulatory molecule 
(ICOS) may also be important in autoimmune tolerance due to its role in Th2-mediated anti-
inflammatory responses [11] (Figure 2). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Antigen-specific and co-stimulatory signal, CTLA-4 
 
 
Cytokines and Thelper subsets 
Cytokines are proteins secreted by the cells of innate and adaptive immunity that mediate 
many functions of these cells (Figure 3). The activation of B cells and phagocytes by CD4+ T 
helper cells depends on secretion of cytokines by the T cells that not only activate the antigen 
presenting cell but can bias its response. T cells an direct the type of antibody secreted in the 
case of a B cell, and the other immune cells recruited in the case of a macrophage, depending 
upon the particular cytokines produced and thus shape the nature of the inflammatory 
response. Pro-inflammatory (Th1) cytokines – IFN-γ, interleukin (IL)-12 – produced by Th1 
cells enhance cellular immune responses, cell-mediated cytotoxicity, and activate 
macrophages. Th2 cytokines called anti-inflammatory cytokines – IL-4, IL-5, IL-6, IL-10, IL-
13 – produced by Th2 cells generate humoral immune response, and antibody production. 
Previous data emphasized the importance of IL-12 driving differentiation of naïve T cells into 
IFN-γ producing Th1 cells essential for cell-mediated immunity [12]. However, mice 
deficient in components of the IFN-γ pathway remain susceptible or develop more severe 
autoimmune diseases, suggesting that these factors are not always necessary in the 
APC
T
CD40LCD40
B7 CTLA-4
MHC
TCR
 
 
 
10 
development or can even regulate such disorders. Recently, other pro-inflammatory cytokines, 
IL-23 and IL-17 have been indicated to play an important role in the establishment of 
autoimmune diseases and T cells producing IL-17 have been dubbed Th17 cells. One of the 
Th17 differentiation pathways is IL-23-dependent andIL-23 is necessary for the survival and 
expansion of Th17 cells; this effect is mediated through the IL-23 receptor (IL-23R) signaling 
pathway [13-15].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Thelper subsets 
 
  
γδT cells 
The vast majority of T cells have an αβTCR and thereby called αβT cells. A small 
subset of T cells called γδT cells have γδTCRs and are αβ-negative. γδT cells express a TCR 
consisting of a γ-chain combined with a δ-chain, composing a distinct T cell population from 
αβT cells. γδT cells are proposed to bridge the innate and adaptive immune responses. They 
are able to produce great amounts of IFN-γ in a short period of time, which is characteristic to 
cells of the innate immune system [16,17]. γδT cells are important regulators of immune 
responses, play a necessary role in protective immune responses against certain pathogens and 
in tumor immunity through provision of an early source of IFN-γ [18]. The Vδ2 subset, 
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expressing a δ2TCR variable chain, represents the majority of adult γδT cells mainly with a 
cytotoxic property [17,19].  
 
iNKT, CD3+CD56+ NKT-like T and MAIT cells 
In the last decades, novel T cell populations have be n described, which may play an 
important role in protection against autoimmunity (Table 1).  
 
Table 1. T cell subsets expressing an invariant αCDR3 
 
 
 
 
 
 
 
A small percentage of αβTcells express molecules specific to NK cells, such as CD56 
in addition to the TCR. Therefore these T cells have been historically termed natural killer T, 
ie. NKT cells. This population bridges the innate and the adaptive immune responses. NKT-
like cells represent a small lymphocyte subpopulation hat has important immunoregulatory 
functions [20,21].  
Kronenberg and Gapin [20] categorized murine NKT cells into several distinct subsets 
based on their TCR repertoire, expression of antigen-presenting co-receptor molecules, and 
their anatomical compartmentalization in the host. Type I NKT cells exhibit a rearrangement 
of the Vα14-Jα18 variable region of the TCR and are either CD4+ or CD4-, CD8- (double 
negative, DN). The responsiveness of these NKT cells is CD1d, a non-conventional MHC 
class I molecule-restricted, and these cells are primarily located in the thymus, liver, spleen, 
and bone marrow. The reactivity of this subset appers restricted to α-galactosylceramide 
(αGalCer) and represents a major c mponent of the overall NKT cell population. This NKT 
subset coexpresses Ly49 receptors that are also found on NK cells.  
The human analogue of the murine Vα14-Jα18 type I NKT cells expresses an 
invariant Vα24-JαQ TCR α-chain paired with TCR β-chain using a biased V gene segment 
(Vβ11). These cells are referred to as invariant NKT (iNKT) or CD1d-restricted NKT cells, 
and reside mostly in the CD4-CD8- (DN) and CD4+ cell subsets [22-24]. Emerging data 
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indicate the functional diversity of human iNKT cells and their involvement in tumor 
immunity and autoimmunity [25-29].  
Besides iNKT cells, the CD3+CD56+ T cell subset contains large granular 
lymphocytes with conventional, diverse αβTCR. Recently, these cells have been termed 
NKT-like cells. The role of NKT-like CD3+CD56+ cells has been suggested and intensively 
investigated in various immune responses, including response to infectious agents, tumor 
rejection and autoimmunity [30-32].  
Along with the identification of Vα24 iNKT cells, another DN T cell population 
expressing an invariant Vα7.2-Jα33 TCR has been described, and named mucosal-associted 
invariant T (MAIT) cells relating to their preferential location, the gut lamina propria [22,33]. 
Similarly to CD1d, a non-classical MHC class Ib molecule, MR1 presents ligands to MAIT 
cells, possibly glycolipids similarly to iNKT cells [34]. In addition to the conserved CDR3α, 
MAIT cells express a restricted Vβ2 and Vβ13 driven by the selecting antigen [35]. So far, 
data about function of human MAIT cells are very limited, partly due to the absence of 
clonotypic antibodies. Their anti-inflammatory role has been proposed for the invariant 
Vα7.2-Jα33 TCR of MAIT cells was found to be present in autoimmune lesions of both the 
central and peripheral nervous system, which correlated with the expression of IL-4 [28,36].  
In addition to iNKT and MAIT cells, two other T cell subsets have been suggested 
expressing an invariant α-chain: Vα4-Jα29 and Vα19-Jα48 TCR, respectively [37].  
Deficiency of human iNKT cells has been described in MS, indicated by a decreased 
frequency in the peripheral blood and absence of the invariant Vα24-JαQ TCR in MS plaques 
despite the presence of Vα24 TCR. Such deficiencies are not characteristic to the chronic 
autoimmun demyelinating disease of the peripheral nervous system, CIDP. Other T cell 
subsets with invariant TCR, ie. MAIT, V α4-Jα29 and Vα19-Jα48 T cells have not been 
affected either in MS [26,29,36]. 
 
Multiple sclerosis 
Multiple sclerosis (MS) is a chronic, progressive disease of the central nervous system, 
which predominantly affects young adults – most peopl  experience their first symptoms of 
MS between the ages of 20 and 40. Pathologically, MS is characterized by the presence of 
areas of demyelination and T cell predominant perivascular inflammation resulting in varying 
neurological symptoms that can range from relatively benign to somewhat disabling to 
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devastating. There are about 2-3 million people suffering from MS in the world, in Hungary 
the number of MS patients is approximately 6,000-10,00  [38].  
Despite a large body of research, the exact etiology f MS remains unclear. The 
current hypothesis for the autoimmune mechanism of MS is that the demyelination of plaques 
is mediated by mainly autoimmune CD4+ Th1 cells recognizing central nervous system 
(CNS) autoantigens due to delayed-type or type IV hypersensitivity. The primary autoimmune 
attack and demyelination result in secondary axonal degeneration responsible for progressive 
disability [39]. In contrast to this theory, another unifying concept has implied that 
oligodendrocyte apoptosis is the very first pathological event in all CNS plaques [40].  In this 
case, autoimmunity may be a secondary event triggered by antigens of dying 
oligodendrocytes and disrupted myelin sheath. The het rogeneous nature of MS pathogenesis 
is reflected by pathological studies suggesting that four different pathological subtypes of MS 
exist depending on the presence of cellular or humoral factors mediating immune responses 
and depletion of oligodendrocytes [41].  
MS is a complex genetic disease mediated by interaction of several genes and 
environmental factors. Family studies revealed thatfamily members of MS patients were at a 
significantly higher risk of developing the disease. In identical twins this risk is 250-fold, in 
siblings 30-fold and in half-brothers and half-sister  10 times higher than that of the average 
population. Based on different genomic coupler analyses and association studies, it is 
assumed today that a tremendous number of different g es play a role in the risk of catching 
the disease (polygenetic inheritance). High-risk genes could not only be responsible for the 
regulation of the immune response but also, for example, for regulation of composition and 
stability of myelin [42].  
 
Stroke 
The World Health Organization’s (WHO) standard definition of stroke is „a focal (or 
at times global) neurological impairment of sudden onset, and lasting more than 24 hours (or 
leading to death) and of presumed vascular origin”.  
Approximately 80% of cases are ischemic, 20% are hemorrhagic. In addition to stroke 
being the third leading cause of death, many survivo s of stroke have to adjust to a life with 
varying degrees of disability [43]. Stroke has a high ncidence worldwide – in the United 
States 700,000 people are affected each year leading to over 150,000 deaths [44]. In Hungary 
approximately 40,000 patients are admitted to hospital with the diagnosis of stroke and stroke 
mortality is extremely high in Central-Eastern European countries [45].  
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While direct neurological deficits cause early deaths, infectious complications prevail 
in the postacute phase of stroke contributing to the poor outcome. 18-28% of patients 
developed a poststroke infection in different studies, the incidence of pneumonia and urinary 
tract infections was the highest [46,47]. The increased susceptibility to infections after stroke 
may suggest early alteration of immune responses. Immunodepression induced by stroke has 
been proposed contributing to the increased susceptibility to infections and thus to the 
negative outcome [48-50]. Impaired T and NK cell responses, particularly a reduced IFN-γ 
production were described in a mouse model of focal cerebral ischemia [51]. Moreover stroke 
led to splenic atrophy characterized by a reduction in organ size and a drastic loss of 
splenocyte number in animal models [52]. Very few human immunological studies have been 
performed in stroke patients so far. Very recently, Vogelgesang et al. [53] revealed reduced 
lymphocyte counts and percentages after ischemic stroke, there was a dramatic loss of T cells 
in the peripheral blood of patients with acute ischemic stroke, within 12 hours from onset of 
stroke symptoms, which gradually normalized. No change was detected in IL-10 serum levels, 
while increased IL-6 levels were measured on admission that continued to rise in the 
following 14 days [53].  
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II. AIMS OF THE STUDIES 
 
Here, we investigated molecular bases of neurological diseases focusing mainly on 
molecules and mechanisms involved in regulating autoimmune tolerance ie. protecting against 
autoimmune diseases. We were particularly interested in the role of innate T cells in immune 
responses within the CNS and the neurogenetical background of CNS autoimmune diseases, 
particularly multiple sclerosis. 
 
A. The role of innate T cells in diseases affecting the central nervous system  
In the recent years, phenotypically and functionally similar iNKT and MAIT cells 
have been suggested to participate in immunoregulation of autoimmunity and immune 
surveillance of tumors.  
We have recently found that Vα24-JαQ iNKT cells were absent in CNS plaques of 
MS, while conventional T cells expressing non-invariant Vα24+ TCR were present. It was not 
clear whether this selective absence of iNKT cells was related to the disease or the special 
immunoregulation and antigens within the CNS. Therefore, we addressed: 
1. Do iNKT cells infiltrate tumors within the CNS similarly to tumors outside the 
CNS? 
2. Can we detect other invariant T cells in tumors with a special emphasis on MAIT 
cells, which may possess similar functions to iNKT cells? 
3. If MAIT cells are present in tumors, what is the inflammatory environment? MAIT 
cells have been suggested to produce Th2 cytokines, but the similarity to iNKT 
cells and recent murine data suggested that the MAIT subset may be functionally 
heterogeneous as well.  
4. What is the relation of MAIT and NKT-like cells in tumors? Do MAIT cells 
express CD56? 
5. Do CD56+ MAIT cells participate in anti-tumor immune responses? 
 
Atherosclerosis and acute ischemic stroke are accompanied by immune responses. We 
may suspect that early changes in immune functions may be related to post-stroke infections 
resulting in poor outcome and high mortality of stroke. Therefore, we examined innate T cells 
and NKT-like cells in the early phase of acute ischemic stroke. We also explored activation of 
leukocytes and its relation to post-stroke infections: 
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6. Are innate T cells including CD3+CD56+ NKT-like cells affected by acute 
ischemic events? 
7. What is the relation of leukocyte activation to post-stroke infections?  
8. Does post-stroke leukocyte activation depend on the duration of ischemia and the 
extent of infarct? 
9. Can we use simple bed-side tests to predict outcome and susceptibility for post-
stroke infections?  
 
B. Association of multiple sclerosis with polymorphisms of genes involved in shaping 
immune responses and regulating autoimmune tolerance 
CTLA-4 is an important molecule to terminate immune responses and thus to prevent 
autoimmunity. Data about association of MS with CTLA4 polymorphisms are conflicting. By 
using a large number of patients, here we examined: 
10. Are polymorphisms of the CTLA4 gene associated with multiple sclerosis? 
11. Do polymorphisms of the CTLA4 gene influence expression of co-stimulatory 
molecules important in terminating or shaping immune responses? 
  
A novel functional Th cell subpopulation (Th17) has recently been described as the 
main autoimmune T cell subset. One of the Th17 differentiation pathways is IL-23-dependent. 
IL-23 is necessary for the survival and expansion of Th17 cells mediated via the IL-23 
receptor (IL-23R) signaling pathway. Association of polymorphisms of IL23R gene has 
recently been suggested in autoimmune inflammatory bowel disease. Therefore, we 
examined: 
12. Are polymorphisms of the IL23R gene associated with multiple sclerosis? 
13. Is IL23R a shared autoimmunity gene? 
 
MS is a complex genetic disease mediated by interaction of several genes and 
environmental factors. In addition, regulation of gene expression is controlled through the 
combinatorial action of multiple transcription factors. Therefore, we performed a gene 
network analysis to examine complex autoimmune processes underlying the pathogenesis of 
MS: 
14. Are there gene expression networks dysregulated in multiple sclerosis? 
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III. SUMMARY OF PAPERS SUPPORTING THESES 
 
A. THE ROLE OF INNATE T CELLS IN DISEASES AFFECTING  THE CENTRAL 
NERVOUS SYSTEM  
 
Paper 1 
Invariant V α7.2-Jα33 TCR is expressed in human kidney and brain tumors indicating 
infiltration by mucosal-associated invariant T (MAIT) cells 
(Int Immunol, October 16, 2008, Epub ahead of print) 
The anti-tumor response of human iNKT cells is well established. A novel T cell 
subset, mucosal-associated invariant T (MAIT) cells, possess similar regulatory properties to 
iNKT cells in autoimmune models and disease, but data about other functions of human 
MAIT cells are very limited, partly due to the absenc  of clonotypic antibodies. In addition, 
our previous data indicated the selective absence of iNKT cells in MS plaques in contrast to 
autoimmune inflammatory demyelinating lesions of the peripheral nervous system and MAIT 
cells. To address whether such deficiency of iNKT cells is related to the CNS environment or 
MS, we examined the presence of four known T cells with invariant αTCRs including that of 
iNKT cells in tumors within and outside of the CNS. The presence of sequences of Vα24-
JαQ (iNKT), Vα7.2-Jα33 (MAIT), Vα4-Jα29 and Vα19-Jα48 TCRs was investigated in 19 
biopsy samples of human kidney cancers and brain tumors by using RT-PCR SSCP clonality 
assay (Figure 4).  
The MAIT clonotype was identified and co-expressed with iNKT clonotype in half of 
the tumors. In contrast, invariant Vα4 and Vα19 T cell clonotypes were not present in tumors. 
Vβ expression of Vα7.2-Jα33 MAIT cells with a restricted Vβ2 and Vβ13 TCR usage was 
further analyzed in tumor samples containing MAIT cells, as well as their antigen-presenting 
molecule, MR1 expression and pro- and anti-inflammatory cytokine environment. All kidney 
tumors with MAIT αTCR also expressed Vβ2 and Vβ13, in contrast to brain tumors, 
suggesting that MAIT cells in CNS tumors may express other Vβ chains as well. All tumors 
positive for MAIT invariant TCR express the antigen presenting molecule MR1, indicating 
that MAIT cells can be locally re-activated. Indeed, a high percentage of infiltrating T cells 
was CD8+ and expressed HLA-DR suggesting activation. The clonal presence of MAIT cells 
in tumors correlated with the expression of pro-inflammatory cytokines but no IL-4, IL-5 and 
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IL-10, suggesting that a pro-inflammatory subset of human MAIT cells may exist. We also 
examined CD56 expression of MAIT cells both in tumor samples and in the peripheral blood 
of tumor patients. Although the MAIT αTCR was identified in both peripheral CD56+ and 
CD56- subsets, tumor infiltrating lymphocytes were CD56 negative.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Our data imply that a CD56- subset of MAIT cells may participate in pro-
inflammatory tumor immune responses similarly to iNKT cells. In addition, MAIT cells may 
have a pro-inflammatory T cell subset, similarly to human iNKT and murine MAIT cells. Our 
data also suggest that the selective absence of iNKT cells in CNS plaques of MS may be 
specific to the disease and not related to the CNS environment. 
 
*** 
Paper 2 
Impaired function of innate T lymphocytes and NK cells in the acute phase of ischemic 
stroke 
 (revised version resubmitted to Stroke) 
While direct neurological deficits cause early deaths, infectious complications prevail 
in the postacute phase of stroke contributing to the poor outcome. The increased susceptibility 
to infections after stroke may suggest early alteration of immune responses, thus 
immunodepression induced by stroke has been proposed. Th  few animal and human studies 
Figure 4.  
Identification of invariant Vα4-
Jα29, Vα7.2-Jα33, Vα19-Jα48 
and Vα24-JαQ T cell receptors. 
Following RT-PCR with Vα (4, 7.2, 19 
or 24) and Cα primers (1), the 
amplified CDR3α regions were 
electrophoresed in non-denaturing 
SSCP gel (2). DNA was transferred to 
a nylon membrane (3) and hybridized 
with biotinylated internal Cα-, Jα-
specific (Jα29, Jα33, Jα48, JαQ) or a 
junctional clonotypic probe 
complementary to the corresponding 
invariant CDR3α (4). An invariant 
CDR3α sequence can be identified 
even by hybridization with Cα or Jα 
probe by moving into the same position 
in different samples (arrow) among 
conventional TCR clonotypes.  
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all addressed the rapid changes in the adaptive arm of the immune system, mainly T cells. We 
analyzed rapid changes in immunological functions of cells of the innate immunity or 
lymphocytes bridging the innate and the adaptive arms of the immune system, all capable of 
shaping subsequent immune responses through rapid pro uction of cytokines and/or 
cytotoxicity. The analyzed cell subsets were Vδ2 T cells, CD3+CD56+ natural killer T (NKT)-
like cells and CD3-CD56+ NK cells. Their frequencies, cytokine production, i tracellular 
perforin, surface Fas ligand (FasL) expression, and NK cytotoxicity were measured in 28 
patients’ peripheral blood obtained within 6 hours and also after 72 hours of ischemic stroke. 
The paired samples were compared both with each other and with 20 healthy controls.  
Percentages of Vδ2, NKT-like and NK cells at 6 and 72 hours after stroke were 
constant and similar to percentages in healthy subjects. In contrast, pro-inflammatory 
intracellular IFN-γ expression by Vδ2 T cells, NKT-like cells and NK cells and IFN-γ 
production by isolated NK cells in culture were low at 6 hours and reached the level of 
healthy subjects’ by 72 hours after stroke. Anti-inflammatory IL-4, IL-5 and IL-10 production 
of NKT-like and NK cells was not altered. Intracellular perforin expression by Vδ2 T cells, 
NKT-like cells and NK cells, and NK cytotoxicity were low at 6 hours and reached the level 
of healthy subjects by 72 hours.  
According to our results, pro-inflammatory and cytotoxic but not anti-inflammatory 
responses of NK, NKT-like and Vδ2 T cells become acutely deficient in ischemic stroke, 
which may contribute to an increased susceptibility to infections. 
 
*** 
Paper 3 
Deficient leukocyte antisedimentation is related to post-stroke infections and outcome 
(J Clin Pathol, 2008, in press ) 
Patients with stroke are more susceptible to infections suggesting possible deficiencies 
of early immune responses, particularly of leukocytes. Here, we examined whether post-
ischemic activation of leukocytes is related to duration of ischemia and extent of infarct. We 
also addressed, if disregulated leukocyte activation might be related to post-stroke infection 
and worsen outcome. We used leukocyte antisedimentatio  rate (LAR) to detect activation of 
leukocytes and correlated LAR with clinical and laboratory parameters. An additional aim 
was to test simple bed-side investigations in predicting outcome and susceptibility for post-
stroke infections early. 
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LAR, a simple test to detect activation of leukocytes was serially examined and 
correlated with blood level of S100β related to extent of infarct, procalcitonin indicat ng 
infection and outcome in patients with acute ischemic events. Venous blood samples were 
taken from 61 healthy volunteers and 49 patients wih acute ischemic events: 38 patients with 
acute ischemic stroke, AIS, and 11 patients with transient ischemic attack, TIA where 
symptoms disappear in 24 hours and cranial CT scan does not indicate infarct. Sampling was 
done within 6 hours, at 24 and 72 hours after onset of symptoms. LAR was significantly 
higher in acute ischemic events within 6 hours after onset of stroke regardless of post-stroke 
infections. In addition, elevation of LAR was delayed and attenuated in TIA in contrast to AIS 
and we also observed a positive correlation between LAR and S100β at 72 hours after the 
onset of ischemic stroke both indicating that the extent of tissue injury correlates with the 
magnitude of innate immune responses. Importantly, a deficiency in early elevation of LAR 
was associated with post-stroke infections and a poor outcome measured by Glasgow 
Outcome Scale in AIS.  
We conclude that an early activation of leukocytes indicated by elevation of LAR is 
characteristic of acute ischemic cerebrovascular events. A delayed and ameliorated leukocyte 
activation represented by LAR is characteristic to TIA in contrast to definitive stroke. Our 
data suggest that acute activation of leukocytes, which has been regarded detrimental so far, 
serves also to prevent post-stroke infections. Our data impy that concept about the post-
ischemic role of leukocytes should be changed and dissected: recruitment of leukocytes in the 
CNS may be damaging but should be separated from the syst mic activation, which may 
prevent post-stroke infections. A disregulated early immune response or deficient leukocyte 
activation may result in an increased susceptibilty to infections in some patients with stroke. 
 
*** 
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B. ASSOCIATION OF MULTIPLE SCLEROSIS WITH POLYMORPH ISMS OF 
GENES INVOLVED IN SHAPING IMMUNE RESPONSES AND REGU LATING 
AUTOIMMUNE TOLERANCE 
 
Paper 4 
Multiple sclerosis and the CTLA4 autoimmunity polymorphism CT60: no association in 
patients from Germany, Hungary and Poland 
(Mult Scler, 2008, 14:153-158)  
For the full activation of T cells, besides the antigen-specific stimulation through TCR, 
a second signal called co-stimulation is necessary. Both APC and T cells will be activated 
during co-stimulation, a sequence of ligand-receptor interactions on the surface of both cells. 
Such interactions are required also for the terminatio  of activation, a mechanism important in 
autoimmune tolerance. This termination is mainly mediated by CTLA-4 (cytotoxic T-
lymphocyte-associated antigen-4) expressed on the surface of T cells upon activation.  
Polymorphisms in the CTLA4 gene region have been associated with susceptibility to 
autoimmune diseases. The recently described single nucleotide polymorphism CT60, located 
in the 3’ untranslated region (3’UTR) of CTLA4 is associated with Graves’ disease, 
thyroiditis, autoimmune diabetes and other autoimmune diseases, however, its role in multiple 
sclerosis (MS) susceptibility has been controversial. Therefore, we conducted a case-control 
association study in a large number of German, Hungarian and Polish MS patients and 
regional control individuals for the CTLA4 CT60 and +49A/G polymorphisms. We also 
performed haplotype analysis. Besides, we examined functional consequences ie. genotype 
differences in the expression of CTLA-4 and ICOS.  ICOS is also important in autoimmune 
tolerance due to its role in Th2-mediated anti-inflammatory responses and susceptibility to 
experimental autoimmune encephalomyelitis (EAE), the animal model of MS is related to 
locus containing genes for both CTLA-4 and ICOS. Splice variants of CTLA-4 modify 
expression of ICOS in such models.  
However, we found no significant association of these polymorphisms or respective 
haplotypes with MS, even when our data were extended with previously published results in a 
metaanalysis thus evaluating 1228 MS and 1440 controls. No association of CT60 genotypes 
with T cell expression of ICOS and CTLA-4 after in vitro stimulation was detected. In 
summary, our data using a large number of cases and co trols contradict to a major effect of 
CTLA4 in MS susceptibility. 
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Paper 5 
3’UTR C2370A allele of the IL-23 receptor gene is associated with relapsing-remitting 
multiple sclerosis 
(Neurosci Lett, 2008, 431:36-38) 
Besides Th1 type cytokines, other pro-inflammatory cytokines, IL-23 and IL-17 have 
been indicated to play an important role in the establishment of autoimmune diseases, and T 
cells producing IL-17 have been dubbed Th17 cells. One of the Th17 differentiation pathways 
is IL-23-dependent and IL-23 is necessary for the survival and expansion of Th17 cells; this 
effect is mediated through the IL-23 receptor (IL-23R) signaling pathway. The IL-23/IL-17 
cytokine axis has been suggested to play an important ole in the development of several 
autoimmune diseases including multiple sclerosis.  
We compared the prevalence of C2370A single nucleotid  polymorphism (SNP) in the 
3’ untranslated region (3’UTR) of the IL-23 receptor gene (IL23R) between 223 patients with 
relapsing-remitting multiple sclerosis (RRMS) and 200 healthy controls. The A2370A 
genotype was significantly over-represented among patients with RRMS (10.8%) and RRMS 
exhibiting oligoclonal bands in the cerebrospinal fluid (12.9%) when compared to healthy 
subjects (5.50%). Multiple regression analysis revealed that presence of AA genotype 
provides a two-fold risk for the development of multiple sclerosis (OR=2.072, 95% CI: 0.988-
4.347, p<0.05) and presence of oligoclonal bands in the CSF (OR=2.554, p=0.03). We did not 
find significant differences when female patients or HLA-DRB1*1501 positive/negative 
patients were separately analyzed and compared to controls. Nor did we find association in 
secondary progressive cases, athough the simple size was small (n=45).  
Besides suggesting association with MS, these data indicate that IL23R represents a 
novel shared susceptibility gene as its association w th several autoimmune diseases including 
inflammatory bowel disease (IBD) and psoriasis has recently been verified. 
*** 
Paper 6 
Aberrant transcriptional regulatory network in T ce lls of multiple sclerosis 
(Neurosci Lett, 2007, 422:30-33) 
Although several data indicated altered gene expression profile in MS using 
microarrays, transcriptional networks, which can regulate a number of genes, have not been 
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examined in MS. In addition, genetic differences may also contribute to altered expression of 
genes. The concordance rate of monozygotic twins is approximately 30 %, while it is less than 
5 % for dizygotic twins, suggesting the involvement of not a single but multiple susceptibility 
genes in the pathogenesis of MS. In addition, regulation of these multiple susceptibility gene 
expressions is controlled again through the combinatorial action of multiple transcriptional 
factors. Therefore, gene network analysis is necessary to evaluate the complex autoimmune 
processes underlying the pathogenesis of MS. 
Therefore, we studied gene expression profile of purified CD3+ T cells isolated from 
Hungarian monozygotic MS twins by DNA microarray analysis and performed gene network 
analysis (Figure 5). 
 Three pairs were concordant, while one pair was discordant for MS. By comparing 
the three concordant and one discordant pairs, we identified 20 differentially expressed genes 
(DEG) between the MS patient and the genetically identical healthy subject. Molecular 
network of 20 DEG analyzed by KeyMolnet, a comprehensive information platform, 
indicated the close relationship with transcriptional regulation by the Ets transcription factor 
family and the nuclear factor NF-κB.  
This novel bioinformatic approach proposes the logical hypothesis that aberrant 
regulation of the complex transcriptional regulatory network contributes to development of 
pathogenic T cells in MS.    
 
 
 
 
 
 
 
 
 
 
               Figure 5. Gene expression network analysis in monozygotic twins with MS 
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IV. PAPERS 
 
 
 
 
 
Paper 1  
 
Invariant V α7.2-Jα33 TCR is expressed in human kidney and brain tumors 
indicating infiltration by mucosal-associated invariant T (MAIT) cells 
(Int Immunol, October 16, 2008, Epub ahead of print) 
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Abstract
The anti-tumor response of human invariant NKT (NKT) cells is well established. A novel T cell subset,
mucosal-associated invariant T (MAIT) cells, possesses similar regulatory properties to NKT cells in
autoimmune models and disease. Here, we examined the clonality of four T cell subsets expressing
invariant aTCR, including Va7.2-Ja33 of MAIT cells, in 19 kidney and brain tumors. The MAIT
clonotype was identified and co-expressed with NKT clonotype in half of the tumors. In contrast, two
other invariant T cell clonotypes (Va4 and Va19) were not present in tumors. Such tumors also
expressed Vb2 and Vb13, the restricted TCRb chain of MAIT cells and the antigen-presenting
molecule MR1. A high percentage of infiltrating T cells was CD81 and expressed HLA-DR suggesting
activation. Although the MAIT aTCR was identified in both peripheral CD561 and CD562 subsets,
infiltrating lymphocytes were CD56 negative. The clonal presence of MAIT cells in tumors correlated
with the expression of pro-inflammatory cytokines but no IL-4, IL-5 and IL-10, suggesting that a pro-
inflammatory subset of human MAIT cells may exist. Our data imply that a CD562 subset of MAIT cells
may participate in tumor immune responses similarly to NKT cells.
Introduction
The heterogeneous T cell repertoire of mainstream lympho-
cytes is generated by random recombination of V, D and
J segments and junctional deletion and insertion of nucleoti-
des. In contrast, innate lymphocytes are characterized by
limited repertoire diversity. The best-characterized invariant
abT cell population, NKT cells, was identified in the early
90s in humans (1, 2). NKT cells express the invariant Va24-
JaQ CDR3 and reside mostly in the CD4ÿCD8ÿ (double
negative (DN)) and CD4+ cell subsets (1, 2). The CD1d rec-
ognition of DN Va24 T cells and the restricted Vb usage de-
fined this subset as the human analog of murine NKT cells
(3, 4). Emerging data indicate the functional diversity of hu-
man NKT cells and their involvement in tumor immunity and
autoimmunity (5–8).
Along with the identification of Va24 NKT cells, another DN
T cell population expressing an invariant Va7.2-Ja33 TCR
has been described (1). Homologous TCR sequences dis-
playing the same CDR3 length could be identified in bovine
and murine DN T cell subsets (Va19.1-Ja26), suggesting an
important physiological function (9). Out of the two TCAV7
genes, most of the conserved Va7+ clones utilize the AV7.2
gene segment in humans (10–12). In addition to the con-
served CDR3a, mucosal-associated invariant T (MAIT)
cells express a restricted Vb2 and Vb13 driven by the select-
ing antigen (9, 10). The preferential location of invariant
Va7.2-Ja33 T cells is the gut lamina propria; hence, the name
MAIT cells has been recently suggested (13). Nevertheless,
MAIT cells are also present in the peripheral blood at a similar
frequency to Va24 NKT cells (0.1–0.2%) and constitute about
up to 15% of DN T cells (10). Va7.2-Ja33 MAIT cells are se-
lected by a non-classical MHC class Ib molecule, MR1
encoded by chromosome 1, similarly to CD1d. Several lines
of evidence suggest that MR1 presents ligands to MAIT cells,
possibly glycolipids, similarly to NKT cells (13–16).
Recent data suggest that MAIT cells are similar to NKT
cells in a number of aspects: both use a semi-invariant
TCR, recognize glycolipids and are activated in a co-receptor-
independent manner, selected and restricted by a monomor-
phic class I-like molecule and characterized by a natural
memory phenotype, suggesting a high-avidity interaction with
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self (8, 9, 12, 13, 16). In NKT cell-deficient mice, NK1.1+
hybridomas express the Va19.1-Ja26+ TCR homologous to
human Va7.2-Ja33 (17). In Va19.1-Ja26 TCR transgenic
mice, the transgenic T cells also express NK1.1, the surface
molecule of NKT cells (18).
So far, data about function of human MAIT cells are very
limited, partly due to the absence of clonotypic antibodies.
In humans, the invariant TCR of MAIT cells was shown to
be expressed in autoimmune lesions of the central nervous
system (CNS) and peripheral nervous system (PNS), which
correlated with the expression of IL-4, suggesting an anti-
inflammatory role and regulating autoimmune response similar
to mice (12, 18, 19). However, a functional diversity similar to
NKT cells has been very recently indicated in mice (20).
In addition to NKT and MAIT cells, two other T cell subsets
expressing an invariant a chain have been suggested.
These additional T cell populations express a Va4-Ja29 and
Va19-Ja48 TCR, respectively (11).
Here, we examined expression of the invariant TCRs of the
four human innate T cells in tumors using single-strand confor-
mation polymorphism (SSCP) clonotype analysis. This method
has been used to detect clonal dominance and expansion of
T cell clones in different T cell subsets, including NKT and
MAIT in autoimmune lesions of the nervous system (12, 19,
21). The selective absence of the invariant Va24-JaQ TCR of
invariant NKT (NKT) cells in CNS plaques of patients with
multiple sclerosis (MS) was previously observed, while con-
ventional Va24 TCRs and invariant TCR of MAIT cells were
present (12, 19). To partly examine whether absence of NKT
cells in CNS plaques might be related to the CNS compartment
or is specific to MS, here we examined tumors inside and
outside the CNS, i.e. malignant brain tumors and kidney can-
cers. In tumors characterized by clonal presence of MAITcells,
we also examined the expression of CD56, pro- and anti-
inflammatory cytokines, restricted TCR-Vb chains and MR1.
Methods
The study protocol was approved by the Regional Local
Ethics Committee. Patients or representatives gave written
permission to perform all procedures only performed due to
medical purposes supporting diagnostic and therapeutic
decisions.
Isolation of messenger RNA and synthesis of cDNA
Nineteen tumor samples were obtained by biopsy or dur-
ing operation (11 clear cell kidney cancer, 6 glioblastoma
and 2 malignant meningioma) and immediately snap frozen
or processed. None of the patients was treated with immu-
nosuppressants or irradiation before or at the time of sam-
pling. Messenger RNA (mRNA) was isolated using RNeasy
Mini Kit (Qiagen, Hilden, Germany). The air-dried pellet was
re-suspended in 20 ll of RNAse-free water and used for
cDNA synthesis by First-Strand cDNA Synthesis Kit (Pharma-
cia Biotech, Uppsala, Sweden, or Amersham Biosciences,
Little Chalfont, Buckinghamshire, UK) using oligo-dT as primer.
SSCP analysis
Briefly, mRNA was isolated from tumor tissues, and cDNA of
aCDR3 regions was amplified by reverse transcription (RT)–
PCR with Va- and Ca-specific primers. Primers and probes
were designed based on the previously published sequen-
ces (12, 21). In brief, 1 ll of the diluted cDNA was used for
each PCR with one of the TCR-Va-specific primers and
a Ca-specific primer. Sense primers specific for Va7.2
(GTCGGTCTAAAGGGTACAGT) and Va19 (GCCACAATAAA-
CATACAGGA) were used in conjunction with the same anti-
sense Ca primer (CAGCTGAGAGACTCTAAAT). Sense
primer for Va4 (ACAGAATGGCCTCTCTGG) was used with an-
other anti-sense Ca primer (ATCGGTGAATAGGCAGACAG). To
detect Va24-JaQ-invariant human NKT cells, RT–PCR was per-
formed as described previously with Va24-specific sense
primer (ACACAAAGTCGAACGGAAG) and Ca-specific anti-
sense primer (GATTTAGAGTCTCTCAGCTG) (21). cDNA
synthesized from mRNA of biopsy samples was amplified for
40 cycles, diluted (1:3) and heat denaturated.
Four microliters of the diluted samples were electrophor-
esed in non-denaturing 4% polyacrylamide gel. DNA was
transfered to Immobilon-S (Millipore Intertech, Bedford, MA,
USA) and hybridized with a biotinylated Ca-specific, Ja-specific
or a-CDR3-specific clonotypic internal probe. Hybridization
with a Ca probe detects all amplified CDR3 sequences
(clonotypes) representing distinct T cell clones. In samples
with a heterogeneous T cell population, the SSCP pattern
is characterized by a smear, while CDR3 sequences of
the dominant or expanding clones appear as distinct
bands reflecting clonality of the repertoire (12, 19, 21). The
probes were as follows: Ca (AAATATCCAGAACCCTGAC-
CCTGCCGTGTACC), Ja29 (CTCTTGTCTTTGGAAAGGGCA-
CAAGACTTTCTGT), Ja33 (TATCAGTTAATCTGGGGCGCTG-
GGACCAAGCT), Ja48 (ATTAACCTTTGGGACTGGAACAAG-
ACTCACCATC) and Va24inv, clonotypic (TGTGTGGTGAGC-
GACAGAGGCTCAACCCTG).
DNA was visualized by subsequent incubations with strep-
tavidin, biotinylated alkaline phosphatase and a chemilumi-
nescent substrate system (PhototopeTM Detection Kit, New
England Biolabs, Inc., MA, USA).
RT–PCR
cDNAs for human b2-microglobulin, IL-4 and IFN-c were am-
plified by RT–PCR as described previously (12, 21). In brief,
1 ll of cDNA was used in 25 ll PCR mixture using PCR Mas-
ter Mix (Promega, Madison, WI, USA). Similar strategies
were used for amplification of other cytokines and MR1
mRNA. The primer sequences and annealing temperatures
are indicated in Table 1. cDNA was amplified in GeneAmp
2700 amplifier (Applied Biosystems) using 39 cycles. The
clonotypic RT–PCR for the detection of the invariant MAIT
TCRa chain was performed as described previously, by us-
ing Va7.2-specific sense and clonotypic invariant Va7.2-
Ja33 anti-sense primers (Table 1) (12).
Flow cytometry and sorting of lymphocyte populations
Thirty milliliter heparinized peripheral blood was obtained from
patients with clear cell kidney cancer, brain tumors and from
healthy subjects. PBMCs were isolated on Ficoll-Paque gradi-
ent (GE Healthcare, Uppsala, Sweden) by density gradient
centrifugation. Fresh, unfixed tumor tissue blocks (;1 cm3)
obtained by nephrectomy were immediately sampled in the
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operation theater from the tumor–kidney border region or from
brain tumors, kept on a humid atmosphere at +4°C and trans-
ported within an hour time to the flow cytometry laboratory.
Tumor tissues were cut into cubic millimeter pieces by a sharp
sterile surgical knife, immersed in 2 ml, pH 7.4, PBS and
pushed gently through a 100-lm microfilter (Millpore). The
cell counts of the filtered tumor cell suspensions were mea-
sured by a ‘routine’ laboratory volumetric hemocytometer
(CellCyn3700, Abbott, USA) and adjusted to 5 3 106 cells
per ml in PBS. After washing in PBS, 1 3 106 PBMCs and
5 3 106 tumor cells were incubated for 30 min at room
temperature with different dual or triple combinations of the
following mAbs: FITC-conjugated anti-CD3 and anti-
CD4; PE-conjugated anti-CD8, anti-CD4, anti-HLA-DR and
allophycoerythrin- or perCP-conjugated anti-CD56 and anti-
CD45 (all antibodies from Becton Dickinson, San Diego, CA,
USA). At least 50 000 cells were analyzed using a FACS Cali-
bur flow cytometer (Becton Dickinson Immunocytometry Sys-
tems, Erembodegem, Belgium) after single gating on
lymphoid cells for all mAb combinations. Tumor cells were
gated out from the tumor-infiltrating lymphocyte populations
by their large forward/side scatter and CD45dim staining char-
acteristics. The percentages of positive cells were calculated
using CellQuest software (Becton Dickinson).
CD56+ cells were positively selected with CD56 MicroBeads
on a MACS Cell Separation Column according to the manu-
facturer’s instructions (Miltenyi Biotec, Bergisch Gladbach,
Germany).
Immunohistochemistry
After endogenous peroxidase blocking, slides were incu-
bated with antibodies against CD3 (Dako, prediluted), CD4
(Labvision, 1:40), CD8 (Labvision, 1:50) and CD56
(Novocastra, 1:50). The antibodies were visualized in an au-
tomated immunostainer (Ventana Medical System).
Results
Detection of the invariant Va24-JaQ TCR sequence in biopsy
samples of kidney cancer and brain tumors
In order to investigate the presence of human NKT cells in
tumor tissues, we applied SSCP clonality assay (21). We
could detect Va24 mRNA in all kidney cancers and six out
of eight CNS tumors. Control kidney and brain samples were
negative for the Va24+ TCR (data not shown). The number of
infiltrating clonotypes varied between two and nine per sam-
ple in kidney cancer, and there was a great variation in the
number and dominancy of certain clonotypes. Furthermore,
a clonotype in the same position was identified in different
samples indicating the presence of a shared, invariant
aCDR3 (Fig. 1). Indeed, hybridization with the invariant clo-
notypic probe revealed a single band. The invariant clono-
type was present in 11 out of 19 cancer tissues (7 out of 11
kidney and 4 out of 8 brain) (Fig. 1).
Detection of the invariant Va7.2-Ja33 TCR sequence in biopsy
samples of kidney cancer and brain tumors
The expression of Va7.2+ clonotypes and the invariant
Va7.2-Ja33 MAIT TCR was examined by previously estab-
lished SSCP method, similar to the detection of NKT TCR
(12, 19). Va7.2+ clonotypes were detected in 8 out of 11 kid-
ney cancer and 6 out of 8 brain tumors. Similar to the Va24+
T cell population, CNS samples were characterized by
smear with a few, less dominant clonotypes compared with
kidney cancers when the membrane was hybridized with
a Ca-specific probe. A common clonotype representing the
Va7.2-Ja33-invariant aCDR3 was found in the Va7.2 reper-
toire confirmed also by hybridization with a Ja33-specific
probe (12). Invariant clonotypes could be detected in 14 out
of 19 cancer samples (8 out of 11 kidney and 6 out of 8 brain
tumors) (Fig. 2). In both kidney and brain tumors, the MAIT
clonotype was more dominant than in the peripheral blood
(PB) (Fig. 2, lower panel).
Search for invariant Va4+ and Va19+ TCR sequences in
tumors
In addition to MAIT and NKT cells, Va4-Ja29+ and Va19-
Ja48+ T cells have been shown to express non-canonical
aCDR3s (11). To investigate their presence among tumor-
infiltrating lymphocytes, we established SSCP clonotypic
assays.
Va19+ mRNA was detected in 5 out of 11 kidney cancers
(45%) but in none of the brain tumors. Similarly, Va4+ mRNA
could be amplified from six kidney cancers (54%), but was
not present in brain tumors. The infiltrating Va4+ repertoire
Table 1. Primer sequences and annealing temperature
Primer sequences (5#–3#) Annealing temperature (°C)
TNF-a F: caatgccctcctggccaat; R: tcggcaaagtcgagatagtc 58
IL-17 F: aatctccaccgcaatgagga; R: acgttcccatcagcgttgat 58
IFN-c F: atgtagcggataatggaactc; R: aacttgacattcatgtcttcc 58
IL-12 F: attctcggcaggtggaggt; R: gcagaatgtcagggagaagt 58
IL-4 F: actgcaaatcgacacctatta; R: atggtggctgtagaactgc 58
IL-5 F: gcttctgcatttgagtttgctagct; R: tggccgtcaatgtatttctttattaag 60
IL-10 F: gaaccaagacccagacatc; R: cattcttcacctgctccac 58
MR1 F: tgggagaggtacactcagc; R: agccacattatctacagcca 58
Vb13A F: gtatcgacaagacccaggc 62
Vb13B F: ggctcatccattattcaaatac 60
Vb2 F: tcatcaaccatgcaagcctg 60
Cb R: gcttctgatggctcaaacac
Va7.2-Ja33 F: gtcggtctaaagggtacagt; R: tgatagttgctatctctcac 58
b2-Microglobulin F: aagatgagtatgcctgccgtg; R: cggcatcttcaaacctccat 58
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was very restricted in kidney cancers indicated by the pres-
ence of a few, well-demarcated clonotypes. In contrast, the
Va19+ T cells expressed heterogeneous aCDR3 (Fig. 3). We
were not able to identify shared Va4+ or Va19+ clonotypes
hybridizing the samples with Ca- or Ja-specific probes
(Fig. 3), suggesting that presence of MAIT and NKT clono-
types in tumors may not be accidental.
Detection of Vb2 and Vb13 TCRb chains expressed by MAIT
cells in kidney and brain tumors
Beside the invariant Va7.2-Ja33 TCRa chain, MAIT cells are
characterized by a restricted Vb2 and Vb13 TCR usage
(9, 10). We examined the expression of these TCRb chains
by RT–PCR. In kidney cancers, all but one sample
expressed Vb2 and Vb13 mRNA, respectively (Fig. 6). In ad-
dition, all the eight samples expressing the MAIT clonotype
were positive for both b chains. In contrast, expression of
these b chains was more limited in brain tumors: Vb2 and
Vb13 sequences could be detected in five samples, and half
of the brain tumors expressing the invariant MAIT aTCR did
not express Vb2 and Vb13.
T cell subtypes in tumors expressing the invariant MAIT aTCR
To further characterize tumor samples expressing invariant
aTCR and restricted TCRb chains of MAIT cells, tissues were
stained with anti-CD3, anti-CD4, anti-CD8 and anti-CD56
Fig. 1. Clonality of the Va24+ T cell repertoire and presence of the
invariant Va24-JaQ clonotype representing NKT cells in kidney and
brain tumors. Tumor tissues obtained from 11 patients with clear cell
kidney cancer (left panel) and eight patients with brain tumor (right
panel) were examined by RT–PCR SSCP clonotypic analysis.
Amplified Va24+ CDR3 was hybridized with a Ca probe (upper
panel) and an invariant, clonotypic CDR3-specific probe (lower
panel). HS indicates a lane for PBMC from a healthy subject. Arrow
shows the position of the clonotype representing the invariant Va24-
JaQ CDR3 in several samples indicating the presence of NKT cells.
Fig. 2. Clonality of the Va7.2+ T cell repertoire and presence of the
invariant Va7.2-Ja33 clonotype representing MAIT cells in kidney and
brain tumors. Tumor tissues obtained from 11 patients with clear cell
kidney cancer (left panel) and eight patients with brain tumor (right
panel) were examined by RT–PCR SSCP clonotypic analysis.
Amplified Va7.2+ CDR3 was hybridized with a Ca probe (upper
panel) and a Ja33-specific probe (lower panel). HS indicates a lane
for PBMC from a healthy subject. Arrow shows the position of the
clonotype representing the invariant Va7.2-Ja33 CDR3 in several
samples indicating the presence of MAIT cells.
Fig. 3. Clonality of the Va4+ and Va19+ T cell repertoire in clear cell
kidney cancer. Tumor tissues expressing Va4+ and Va19+ TCR were
further analyzed by SSCP clonality analysis using Ca-specific probe
to detect clonotypes with invariant TCR. No shared clonotypes are
present in five kidney cancers positive for Va4+ TCR (left panel) and
seven kidney cancers expressing Va19+ TCR (right panel)
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antibodies. All kidney and brain tissues were positive for
CD3+ lymphocytes, as expected. Only a few lymphocytes
expressed CD4 in contrast to CD8 co-receptor (Fig. 4).
FACS staining of infiltrating lymphocytes confirmed that
HLA-DR+CD8low T cells were the major subset in tumors
expressing MAIT TCRs (Fig. 4).
However, infiltrating T lymphocytes did not express CD56 in
either tumor, despite of previous data suggesting expression
of this molecule by NKTand MAIT cells as well (4, 9) (Fig. 5).
Detection of the invariant MAIT aTCR in CD56 subsets of
PBMC obtained from patients with kidney and brain tumors
The absence of CD56+ T cells in tumors expressing MAIT
and NKT TCR was unexpected (Fig. 5). Therefore, we exam-
ined the expression of the invariant Va7.2-Ja33 TCRa chain
in peripheral CD56+ and CD56ÿ T cell subsets isolated from
PB of five patients with kidney cancer, five patients with
brain tumors and five healthy subjects. CD56+ and CD56ÿ
subsets were isolated by MACS from PB, and the invariant
MAIT TCR was amplified by clonotypic RT–PCR. Both
CD56+ and CD56ÿ subsets obtained from patients and
healthy controls expressed MAIT TCR (Fig. 5).
Cytokine and MR1 expression in kidney and brain tumors
infiltrated by MAIT and NKT cells
While the functional heterogeneity of NKT cells is well estab-
lished, MAIT cells are regarded as a T cell population pro-
ducing primarily Th2 cytokines (9, 12, 17, 18). This view has
been recently challenged in mice (20). Therefore, we
attempted to examine the cytokine environment in tumors
expressing MAIT and NKT TCR (Fig. 6). Tumor samples were
examined for the presence of MAIT and NKT clonotypes by
RT–PCR SSCP and correlated with pro/anti-inflammatory cy-
tokine expression examined by RT–PCR in the same sam-
ples (Tables 2 and 3).
The majority of tumors expressed pro-inflammatory (Th1
and Th17) cytokines. IL-12 and tumor necrosis factor (TNF)-
a mRNA were equally well represented in both kidney and
brain tumors. In contrast, only a single brain tumor
expressed IL-17 and none was positive for IFN-c mRNA, al-
though both cytokines were abundantly expressed in kidney
cancer (Tables 2 and 3).
A similar bias was observed in the case of anti-inflamma-
tory cytokines: only IL-10 mRNA was detected in abundance
in kidney cancers. Three kidney cancers were also positive
for IL-4 and IL-5 mRNA, but these cytokine messages were
not detected in brain tumors at all. In addition, three of the
kidney cancers and three of the brain tumors expressed only
pro-inflammatory cytokines despite the presence of the in-
variant MAIT TCR (Tables 2 and 3).
To examine whether infiltrating MAIT cells may be locally
activated through antigen recognition, expression of MR1
was also checked (Tables 2 and 3 and Fig. 6). All but one
kidney cancer and four out of six brain tumors expressing
MAIT TCR were positive for MR1 mRNA. In contrast, we
identified 4 out of 19 tumors, which expressed MR1 but no
MAIT invariant TCR.
Fig. 4. Phenotype of infiltrating T lymphocytes in tumor tissues
expressing the invariant MAIT aTCR. Surface expression of CD8 by
immunohistochemistry (3400) and CD8/HLA-DR ontumor-infiltrating
lymphocytes analyzed by flow cytometry is shown in a representative
sample.
Fig. 5. Expression of CD56 in tumors expressing MAIT aTCR and
presence of MAIT aTCR in peripheral CD56+ and CD56ÿ lymphocyte
subsets obtained from cancer patients and controls. (A) CD56+ and
CD56ÿ lymphocyte subsets were isolated from the peripheral blood
of healthy controls, patients with clear cell kidney cancer and patients
with brain tumors by MACS. Purity of the sorted population was
checked by flow cytometry. Expression of b2-microglobulin (upper
panel) and the invariant MAIT aTCR by a clonotypic RT–PCR (lower
panel) was examined in the CD56+ and CD56ÿ subsets. (B) Clear
cell kidney cancer and brain tumors expressing the MAIT aTCR were
examined for the expression of CD56 by immunohistochemistry. The
positive staining of CNS served as positive control (brown, 3200).
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Discussion
The role of NKT cells in tumor immunity is well established
(5, 22, 23). In contrast, other innate T lymphocytes express-
ing canonical abTCR have not been examined. A novel in-
nate T cell subset, MAIT cells, is particularly interesting
since phenotypic and functional similarities to NKT cells have
been already suggested (8, 9, 12, 15–18). Here, we exam-
ined the clonality of those T cell repertoires in tumors, which
contain innate lymphocytes with invariant TCRa chains (Va4,
Va7.2, Va19 and Va24). The applied method (RT–PCR
SSCP) has the advantage of assessing clonality and clonal
dominance beside the examination of TCR expression. After
the amplified aCDR3 cDNA sequences are separated by
SSCP electrophoresis, hybridization with a Ca-specific probe
visualizes the particular Va T cell repertoire. The presence of
invariant TCRa chains can be judged in this whole repertoire
and further confirmed in a more restricted T cell repertoire
by a subsequent hybridization with a Ja- or invariant
aCDR3-specific clonotypic probe. After establishing SSCP
clonality assay for the identification of NKT cells in autoim-
mune lesions, our method has been applied in other patho-
logical studies and data were confirmed by different
methodologies (24–27). Particularly, we modified the method
to detect invariant Va7.2-Ja33 T cells, later termed MAIT
cells, in autoimmune lesions (12, 19).
Out of the analyzed four T cell sub-populations, only invari-
ant Va24-JaQ NKT and Va7.2-Ja33 MAIT cells could be
identified in tumor tissues. Although both Va4+ and Va19+
TCR were present in about half of the kidney cancers, no
identical clonotypes indicating an invariant aCDR3 were
detected in these repertoires. In brain tumors, even the non-
canonical Va4+ and Va19+ clonotypes were absent. These
data suggest that MAIT and NKT cells are the major innate
abTCR lymphocyte subsets to infiltrate human tumors and
may indicate that presence of these T cell subsets in tumors
is not accidental but rather specific. Indeed, the clonal dom-
inance of MAIT and NKT was superior to PB.
The number of infiltrating Va7.2 and Va24 clonotypes var-
ied between two and nine per sample in kidney cancer and
there was a great variation in the number and dominancy of
certain clonotypes. In contrast, brain tumors had a more
restricted number and less dominancy of clonotypes. These
data suggested that although Va7.2+ and Va24+ T cells
were present in both PNS and CNS tumors, kidney cancers
were infiltrated with more heterogeneous T cell populations.
Alternatively, T cells died in the CNS tumors. We also ob-
served a more restricted Va7.2+ and Va24+ T cell repertoire
in autoimmune CNS lesions, compared with autoimmune de-
myelinating lesions of the PNS (12, 21). Accordingly, our
data may indicate that within the total Va24+ and Va7.2+
repertoire, both MAIT and NKT cells represent relatively more
dominant populations in CNS compared with kidney tumors.
Moreover, presence of NKT cells in CNS tumors contrasted
to autoimmune CNS lesions, where NKT cells were rarely
detected despite the presence of conventional Va24+ T cells
(21). Detection of NKT cells in CNS tumors indicates that ab-
sence of NKT cells is unique to autoimmune infiltrates and is
not related to the special immunoregulation of the CNS.
The presence of MAIT cells in tumors indicated by the ex-
pression of invariant MAIT TCR clonotypes is a novel finding,
but not unexpected considering the similarities to NKT cells.
The anti-tumor response of NKT cells has already initiated
human clinical trials to treat cancer (23, 28–30). Presence of
NKT cells or the invariant Va24-JaQ TCR has been shown in
Fig. 6. Expression of Vb2, Vb13, MR1 and cytokines in tumor tissues
expressing MAIT aTCR. Expression of cytokines, TCR-Vb chains and
MR1 was determined by RT–PCR in a representative sample of clear
cell kidney cancer (#1) expressing the invariant MAIT aTCR (see
Tables 2 and 3) (lanes indicate: 1 = Vb13A, 2 = Vb13B, 3 = Vb2,
4 = TNF-a, 5 = IFN-c, 6 = IL-17, 7 = IL-12, 8 = IL-10, 9 = IL-4 and
10 = MR1).
Table 2. Expression of cytokines, MR1 and TCRa chains of T cell populations with invariant CDR3a in clear cell kidney cancers
1 2 3* 4 5 6* 7 8 9* 10 11
TNF-a + + ÿ + + + + + + + +
IL-12 + + ÿ + + + + + + + +
IFN-c + ÿ + + + + + ÿ ÿ ÿ ÿ
IL-17 + + ÿ + ÿ + + + ÿ + +
IL-4 + ÿ ÿ ÿ ÿ ÿ ÿ ÿ ÿ ÿ ÿ
IL-5 ÿ ÿ ÿ + ÿ ÿ + ÿ ÿ ÿ ÿ
IL-10 + + ÿ + + ÿ + + ÿ ÿ ÿ
MR1 + + + + + + + + ÿ + +
NKT + + + + ÿ ÿ + ÿ + + ÿ
MAIT + + + + + + ÿ + + ÿ ÿ
Numbers in italics indicate individual tumor samples. The number of samples corresponds to those in Figures 1 and 2. MAITand NKT indicate the
presence of the invariant Va7.2-Ja33 and Va24-JaQ TCR, respectively. The expression of invariant Va7.2-Ja33 and Va24-JaQ TCR was examined
by RT–PCR SSCP clonotypic analysis, and the expression of cytokines and MR1 was examined by RT–PCR (see Methods). Asterisks indicate
those samples where no IL-4, IL-5 and IL-10 mRNA could be detected despite the presence of the invariant MAIT TCRa chain.
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human tissue samples (21, 31–33), including tumors in situ
(34–36). However, the expression of the Va7.2-Ja33 rear-
rangement was only examined and found in autoimmune
and cutaneous sarcoid lesions, suggesting that MAIT cells
can infiltrate tissues as well (12, 31). Although the invariant
MAIT TCR has not been examined in tumors so far, the re-
stricted Vb2 and especially Vb13 TCRs expressed by MAIT
cells have been already shown in a number of tumors
(37–41). In addition, several studies indicated an in vitro cy-
tolytic activity of infiltrating Vb13+ T cells, particularly with
a CD8 phenotype, both characteristic of MAIT cells (39–41).
Indeed, kidney and brain tumors expressing the invariant
MAIT TCR were infiltrated by CD8+ T cells in our study.
These CD8+ T cells also expressed HLA-DR, indicating an
activated state. Of note, the invariant MAIT and NKT TCR
were co-expressed in about half of the tumor samples re-
gardless of compartmentalization, suggesting that MAIT and
NKT cells infiltrate cancers together.
We also examined the presence of CD56 molecule on infil-
trating T cells, which can be connected to cytotoxicity and
can be expressed by both NKT and MAIT cells (4, 9). How-
ever, T cells in kidney cancer and brain tumors were nega-
tive for CD56. Therefore, we examined whether peripheral
MAIT cells obtained from patients with these cancers alter
expression of CD56 compared with healthy controls. Since
no antibody is available to detect MAIT cells, we sorted
CD56+ and CD56ÿ subsets from the peripheral blood and
applied a clonotypic PCR to identify the presence of MAIT
cells in these subsets. The invariant Va7.2-Ja33 TCR mes-
sage could be amplified in both CD56+ and CD56ÿ sub-
sets, similar to healthy subjects. Thus, although part of
peripheral MAIT cells express CD56 in cancer patients, the
tumor-infiltrating MAIT cells may comprise a CD56ÿ subset.
MAIT cells represent a novel T cell population with similar
phenotypic and functional properties to NKT cells (8, 9, 12,
15–18). Their regulatory role has been already addressed in
autoimmunity and may be related to anti-inflammatory cyto-
kines produced or induced by MAIT cells. In mice, they can
protect against autoimmune inflammation of the CNS by an
increased IL-10 production through interactions with B cells
(18). In humans, the invariant MAIT TCR was detected in au-
toimmune lesions in connection with expression of IL-4 and
IL-10 mRNA (12). However, recent data indicated a heteroge-
neous cytokine production by murine MAIT cells, similar to
NKT cells (20, 42). Considering the presence of MAIT cells
in tumors, the suggested similarities to human NKT cells with
anti-tumor activity due to production of pro-inflammatory
cytokines and the functional heterogeneity of murine MAIT
cells, we correlated pro- and anti-inflammatory cytokine ex-
pression in tumors with the presence of MAIT clonotypes.
Pro-inflammatory cytokines were widely expressed in both
kidney cancers and brain tumors, as expected. The only
abundantly expressed anti-inflammatory cytokine was IL-10,
which may both suppress and stimulate anti-tumor immune
responses (43). In addition, only pro-inflammatory cytokines
were detected in six tumors expressing the invariant MAIT
TCR. The correlation of pro-inflammatory cytokines with
MAIT clonotypes may indicate that human MAIT cells may
have a pro-inflammatory subset, similar to human NKT and
murine MAIT cells (20, 42). Besides expression of cytokines,
tumors also expressed MR1, the antigen-presenting mole-
cule of MAIT cells. In the majority of tumors, MR1 was
co-expressed with the invariant MAIT TCR, indicating that
MAIT cells may have the possibility to be locally activated
by ligands presented by MR1 and possibly contribute to the
cytokine environment and cytotoxicity (15, 16).
Our data also emphasize the immunological differences of
tumors located outside and within the CNS. First, there was
a difference in the number and dominancy of both Va24
and Va7.2 clonotypes between tumors located in different
compartments. In addition, while Vb2 and Vb13 expression
was obvious in all tumors presenting the invariant MAIT clo-
notypes in kidney cancer, some of the brain tumors did not
disclose Vb2 and Vb13 TCR, indicating that a subset of
MAIT cells may express other b chains in CNS tumors. In
kidney cancer, pro-inflammatory cytokines IFN-c and IL-17
were abundantly present. In contrast, none of the brain
tumors expressed IFN-c and only one tumor was positive for
IL-17 mRNA. This bias was characteristic only of Th1/Th17
cytokines since TNF-a and IL-12, cytokines important in
anti-tumor responses, were equally well represented in kid-
ney and brain tumors. The number of malignant gliomas
and meningiomas was not enough to examine differences
regarding MAIT, NKT cells and cytokines.
Table 3. Expression of cytokines, MR1 and TCRa chains of T cell populations with invariant CDR3a in brain tumors
1* 2* 3 4 5 6 7 8*
TNF-a + + + + + + + ÿ
IL-12 + + + + + + + +
IFN-c ÿ ÿ ÿ ÿ ÿ ÿ + +
IL-17 ÿ ÿ + ÿ ÿ ÿ ÿ ÿ
IL-4 ÿ ÿ ÿ ÿ ÿ ÿ ÿ ÿ
IL-5 ÿ ÿ ÿ ÿ ÿ ÿ ÿ ÿ
IL-10 ÿ ÿ ÿ ÿ + + + ÿ
MR1 ÿ + + + ÿ + + +
NKT ÿ + ÿ ÿ ÿ + + +
MAIT + + ÿ ÿ + + + +
Numbers in italics indicate individual tumor samples. The number of samples corresponds to those in Figures 1 and 2. MAITand NKT indicate the
presence of the invariant Va7.2-Ja33 and Va24-JaQ TCR, respectively. The expression of invariant Va7.2-Ja33 and Va24-JaQ TCR was examined
by RT–PCR SSCP clonotypic analysis, and the expression of cytokines and MR1 was examined by RT–PCR (see Methods). Asterisks indicate
those samples where no IL-4, IL-5 and IL-10 mRNA could be detected despite the presence of the invariant MAIT TCRa chain.
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In summary, our data indicate that a novel NKT-like T cell
population, MAIT cells infiltrate tumors similar to NKT cells,
while other invariant T cell subsets may not be present. The
co-expression of MR1 and MAIT TCR in tumors suggests
that MAIT cells may be locally activated. The co-expression
of pro-inflammatory cytokines and the invariant MAIT TCR in
the absence of Th2 cytokine messages in tumors may sug-
gest functional heterogeneity of human MAIT cells. Our data
also imply that MAIT cells in tumors may belong to a CD56ÿ
subset and express CD8 and HLA-DR. Considering the im-
portance of NKT cells in anti-tumor responses represented
even by human drug trials, the functional similarities be-
tween MAIT and NKT cells and the co-expression of the two
invariant TCRs in tumors, our data indicate that beside NKT
cells, MAIT cells may be also considered in anti-cancer
treatment strategies.
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Abbreviations
CNS central nervous system
DN double negative
MAIT mucosal-associated invariant T
mRNA messenger RNA
MS multiple sclerosis
NKT invariant NKT
PB peripheral blood
PNS peripheral nervous system
RT reverse transcription
SSCP single-strand conformation polymorphism
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ABSTRACT  
Background and Purpose: Functional alterations of innate lymphocytes, which can amount 
rapid immune responses and shape subsequent T cell reactions, were examined in the acute 
phase of ischemic stroke. Methods: Frequencies, intracellular perforin and IFN-γ expression 
of Vδ2 T cells, CD3+CD56+ natural killer T (NKT)-like and CD56+ natural killer (NK) cells 
were examined sequentially in the peripheral blood of 20 healthy controls and 28 patients 
within 6 hours of the onset of acute ischemic stroke and after 72 hours by flow cytometry. 
Pro- and anti-inflammatory cytokine production of isolated NKT-like and NK cells following 
in vitro activation was measured by cytometric bead array. NK cytotoxicity was examined in 
the peripheral blood mononuclear cells. Results: Percentage of Vδ2, NKT-like and NK cells 
at 6 and 72 hours after stroke were constant and similar to percentages in healthy subjects. In 
contrast, pro-inflammatory intracellular IFN-γ expression by Vδ2 T cells, NKT-like cells and 
NK cells and IFN-γ production by isolated NK cells in culture was low at 6 hours and reached 
the level of healthy subjects by 72 hours after stroke. Anti-inflammatory IL-4, IL-5 and IL-10 
production of NKT-like and NK cells was not altered. Intracellular perforin expression by 
Vδ2 T cells, NKT-like cells and NK cells, and NK cytotoxicity was low at 6 hours and 
reached the level of healthy subjects by 72 hours. Conclusions: Pro-inflammatory and 
cytotoxic responses of NK, NKT-like and Vδ2 T cells become acutely deficient in ischemic 
stroke, which may contribute to an increased susceptibility to infections.        
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INTRODUCTION 
Stroke is associated with high mortality and morbidity, and stroke survivors often 
remain permanently disabled. While direct neurological deficits cause early deaths, infectious 
complications prevail in the postacute phase of stroke contributing to the poor outcome.
1-6
Such an increased susceptibility to infections after stroke may suggest early alteration of 
immune responses.
7-9
 Recently, acute deficiency of T cells has been indicated in experimental 
stroke models.
10,11
 Very recently, dramatic loss of T cells in the peripheral blood of patients 
with acute ischemic stroke, within 12 hours from onset of symptoms, has been indicated.
12
These few studies all addressed the rapid changes in the adaptive arm of the immune system, 
mainly T cells. Cells of the other part of the immune system, innate immunity can initiate 
immediate non-antigen specific reactions in contrast to T cells. In addition, particular 
lymphocyte subsets including specific innate T cell populations bridge the adaptive and innate 
immune responses and are able to amount a rapid immune response either through 
inflammatory cytokine production or cytotoxicity. These mechanisms are important in 
defense against pathogens and also shaping subsequent adaptive T cell responses. Such innate 
lymphocyte subsets have not been thoroughly examined in the acute phase of ischemic stroke. 
T cells express a T cell receptor (TCR) consisting of a -chain combined with a -
chain, composing a distinct T cell population from the well-known T cells. T cells have 
been proposed to bridge the innate and adaptive immune responses.
13,14
 They are able to 
produce great amounts of interferon-γ (IFN-) in a short period of time, which is characteristic 
to cells of the innate immune system.
13,14
T cells are important regulators of immune 
responses, play a necessary role in protective immune responses against pathogens and tumors  
through provision of an early source of IFN-.
15
 The V2 subset, expressing a 2 TCR 
variable chain, represents the majority of adult T cells mainly with a cytotoxic property.
14,16
    
Natural killer T (NKT)-like CD3
+
CD56
+
 cells are unique T cells co-expressing a T-
cell receptor complex (CD3) and NK receptors (CD56).
17
 The role of NKT-like cells have 
been suggested and investigated in various immune responses, including response to 
infectious agents,
18
 tumor rejection,
19,20
 and autoimmunity.
21,22
 This subset also includes 
invariant NKT (iNKT) cells being able to produce large quantities of pro-inflammatory IFN-γ
and anti-inflammatory cytokines such as interleukin (IL)-4 and IL-10,
17,23
 and capable of 
activating NK cells as well.
24 
  
Natural killer (NK) cells are crucial components of the innate immune system, which 
are able to rapidly produce abundant cytokines, mainly IFN-, and lyse target cells without 
prior sensitization.
25,26
 NK cells play a key role in resistance to infections and destruction of 
40
tumor cells.
25,26
 They express CD56 on their surface, which is widely used as an NK cell 
marker to identify them, and lack the expression of CD3.
25,26
 Assistance by NK cells in the 
development of adaptive immune responses has recently been shown as well.
27 
      
Perforin and Fas/Fas ligand (FasL) pathways are the two major mechanisms of 
cytotoxicity.
28,29
 Exocytosis of cytotoxic granules containing pre-formed perforin and serine 
esterase molecules leads to cell lysis by forming pores in target cell membranes.
28-30
 Perforin 
is a marker of cytotoxic cells.
30,31
 FasL produced by effector cells induces apoptosis through 
Fas, its receptor on target cell surfaces. The Fas/FasL-mediated apoptotic pathway thus 
depends on cell-surface ligand-receptor interaction.
28,29,32
Here, we analyzed functional alterations in cytokine production and cytotoxicity of 
innate lymphocyte subsets capable of shaping adaptive T cell responses in the acute phase of 
ischemic stroke.
MATERIALS AND METHODS  
The study protocol was approved by the Regional Local Ethics Committee.  
Patients and samples. Altogether 28 Hungarian patients with acute ischemic stroke 
(16 males, 12 females, mean age: 62 years ± 2.08 years) were prospectively studied and 20 
healthy controls were included in this study. All patients were admitted to the Department of 
Neurology, University of Pecs, Hungary. Written informed consent was obtained from all 
patients or their authorized representative. Exclusion criteria were infectious diseases, fever 
<4 weeks before stroke, elevated white blood cells (WBC), erythrocyte sedimentation rate 
(ESR), high-sensitivity C-reactive protein (hsCRP, cut-off value <10 mg/L), procalcitonin 
(PCT, cut-off value <0.05 ng/mL) on admission, positive chest X-ray, hemorrhagic stroke 
defined by an acute cranial CT scan, transient ischemic attack (TIA, based on the non-
persistency of clinical signs and cranial CT scan after 24 hours) and decline to participate in 
the study. Patients admitted to hospital more than 6 hours after symptom onset were excluded 
too. Twenty-two patients had large territorial and 6 patients had lacunar infarct. In 8 cases, 
stroke was caused by embolism either cardiogenic (n=5) or arterial (n=3). All but one patients 
had infarct in the anterior circulation. Control CT scan showed hemorrhagic transformation in 
a single case only. Peripheral blood was drawn from the cubital vein two times from each 
patient within 6 hours from symptom onset and after 72 hours. Clinical data were collected on 
admission and at 72 hours. Outcome measures were obtained at discharge from hospital 
(Table 1). The National Institutes of Health Stroke Scale (NIHSS) was assessed as a 
quantitative measure of stroke-related neurological deficit on admission and at 72 hours.  
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Table 1 
Cell isolation and flow cytometry. Peripheral blood mononuclear cells (PBMCs) 
were isolated from heparinized venous blood on Ficoll-Paque gradient (AP Hungary Kft. 
Budapest, Hungary) by density gradient centrifugation. After washing in phosphate-buffered 
saline (PBS), 1x10
6
 PBMCs were incubated for 30 minutes at room temperature with different 
dual or triple combinations of the following anti-human monoclonal antibodies (mAb): 
fluorescein isothiocyanate (FITC)-conjugated anti-CD3, anti-V2 T cell receptor, 
phycoerythrin (PE)-conjugated anti-FasL (CD178), anti-IFN-, anti-perforin, and 
allophycocyanin (APC)-conjugated anti-CD56 (all antibodies from BD Pharmingen, Soft 
Flow Hungary Kft., Pécs, Hungary). In the case of IFN- staining, PBMCs underwent a 4-
hour cytokine stimulation with ionomycin, brefeldin A and phorbol-myristate-acetate (PMA) 
(all from Sigma-Aldrich Kft., Budapest, Hungary) prior to the immunostaining. In the case of 
perforin and IFN- stainings PBMCs were permeabilized with FACS Permeabilizing Solution 
2 (BD Biosciences, Soft Flow Hungary Kft., Pécs, Hungary) before adding the respective 
antibody. After incubation, the samples were washed in PBS and resuspended in 4% 
paraformaldehyde, stored at 4ºC in dark to be processed for FACS analysis 24 hours at the 
latest following fixation. At least 50,000 cells were analyzed using a FACS Calibur flow 
cytometer (Becton Dickinson Immunocytometry Systems, Erembodegen, Belgium) after 
single gating on lymphoid cells for all mAb combinations. The percentages of positive cells 
were calculated using CellQuest software (Becton Dickinson, San Diego, CA, USA). 
Demographic and clinical data of subjects
  Patients, acute 
ischemic stroke   
n=28 
Healthy 
subjects    
n=20 
Age (year, mean, range)  62 (40-83) 45.1 (26-64) 
Sex : Male 16 7 
         Female 12 13 
NIHSS 6h (median, range) 10 (4-19) N/A 
NIHSS 72h (median, range) 6 (1-22) N/A 
GOS at discharge (median, range) 4 (1-5) N/A 
Length of stay (day, mean, range) 9.04 (4-27) N/A 
42
NK and NKT-like CD3
+
CD56
+
T cell separation and Cytometric Bead Array 
(CBA). Natural killer and CD3
+
CD56
+ 
T cells were separated by MACS Cell Separation 
Technology (all reagents and instruments from Miltenyi Biotec, Frank Diagnosztika Kft., 
Budapest, Hungary). PBMCs were first magnetically labelled with CD56 MicroBeads 
according to the manufacturer’s instructions and CD56
+
 cells were positively selected on the 
cell separation column. In the next step, the magnetic beads bound to the cell surface were 
enzymatically released from the CD56
+
 cells, which were then magnetically labelled with 
CD3 MicroBeads and the CD3
+ 
subpopulation positively selected to compose the CD3
+
CD56
+ 
T cell population. The remaining fraction of the CD56
+ 
cells, which did not bind the CD3 
beads composed the CD3
-
CD56
+
 NK cell population. Both cell populations were stimulated 
with ionomycin and PMA (Sigma-Aldrich, Sigma-Aldrich Kft., Budapest, Hungary) in RPMI 
1640 Medium containing 10% foetal bovine serum, penicillin and streptomycin (all from 
Invitrogen, Csertex Kft., Budapest, Hungary) overnight for cytokine production. The levels of 
IL-2, IL-4, IL-5, IL-10, IFN- and tumor necrosis factor (TNF)- were determined from the 
culture supernatants with Cytometric Bead Array (CBA) (#550749, BD Biosciences, Soft 
Flow Hungary Kft., Pécs, Hungary) using different capture beads according to the 
manufacturer’s instructions to detect the respective cytokines. Samples were analyzed right 
after the experiment on a FACS calibur flow cytometer (BD Immunocytometry Systems, 
Erembodegen, Belgium) calculating the amount of cytokines with CBA Software (BD 
Biosciences, San Diego, CA, USA).  
Cytotoxicity. The cytotoxic activity of NK cells was determined with a non-
radioactive, colorimetric cytotoxicity assay (#G1780, Promega, Bio-Science Kft., Budapest, 
Hungary). PBMCs containing NK cells were co-cultured with K562 cells, conventional target 
cells of NK cells (NK-sensitive erythroleukaemia cell line)
33,34
 for 4 hours at 37ºC in 40:1, 20: 
1 and 10:1 effector-to-target ratios in a U-bottom 96-well tissue culture plate, according to the 
manufacturer’s instructions. Absorbance of the final color product was recorded by a standard 
96-well plate reader (Thermo Labsystems, Franklin, MA, USA) at 492 nm. Cytotoxicity was 
expressed as the percentage of lysed target cells in each effector-to-target ratio.        
Statistical analysis. Statistical comparisons were made by using one- and two-tailed 
Student’s t-tests. The results were expressed as the mean value±standard error of the mean 
(SEM). Differences were considered significant when the value of P was equal to or less than 
0.05. 
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RESULTS
Innate peripheral lymphocyte frequencies in the acute phase of ischemic stroke  
In order to investigate the acute innate cellular immune responses in ischemic stroke, 
peripheral blood (PB) samples were acquired within 6 hours and after 72 hours of symptom 
onset and compared both with each other and with healthy controls. We particularly focused 
on innate T lymphocytes like γδT cells, CD3+CD56+ NKT-like cells and CD3-CD56+ NK 
cells, which are capable of rapidly producing cytokines and performing cytotoxicity. The 
frequency of V2
+
, NKT-like T cells and NK cells in the PB was not different, when samples 
obtained within 6 hours after onset of stroke were compared to samples obtained 72 hours 
later. In addition, samples taken from patients did not differ when compared to healthy 
controls (Table 2). 
Table 2 
Cytokine production of innate lymphocyte subsets in the acute phase of ischemic stroke 
Intracellular IFN-γ  production. Next, intracellular IFN-γ expression was analyzed by flow 
cytometry in V2
+
 T cells, CD3
+
CD56
+ 
NKT-like, and NK cells (Figure 1). The expression 
of IFN-γ was significantly higher in all subsets after 72 hours compared to samples obtained 
within 6 hours from the beginning of ischemic stroke. In order to define whether the baseline 
IFN- at 6 hours was deficient or normal, data were obtained from healthy individuals as well. 
IFN-γ expression in healthy subjects corresponded to percentages of IFN-γ producing cells at 
72 hours of patients in all subsets, and differed significantly from percentages at 6 hours in 
CD3
+
CD56
+ 
NKT-like and Vδ2+ T cells. 
Innate lymphocyte frequencies in the peripheral blood
Patients, acute ischemic 
stroke 
Percentage of PBL Healthy 
subjects 
within 6 hours after 72 hours
V2 T % 2.02 ± 0.54 1.37 ± 0.24 1.66 ± 0.25 
CD3+CD56+ NKT-like % 4.41 ± 1.56 6.22 ± 1.37 5.75 ± 1.37 
CD3-CD56+ NK % 17.34 ± 2.23 16.34 ± 2.19 16.63 ± 2.34 
mean±SE 
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Pro- and anti-inflammatory cytokine production. Pro- and anti-inflammatory cytokine 
production of isolated CD3
+
CD56
+ 
NKT-like and NK cells were also analyzed. NK and NKT-
like subsets were separated by magnetic beads, stimulated for 24 hours by PMA/ionomycin 
and IFN-, TNF-, IL-2, IL-4, IL-5 and IL-10 production was measured in the supernatants. 
In case of NK cells, significantly higher IFN- levels were detected at 72 hours compared to 6 
hours after the beginning of stroke in accordance with data obtained by the flow cytometric 
analysis (37,6 ng/ml vs. 21,8 ng/ml p<0,05). The levels of the other investigated cytokines 
were not different (data not shown).   
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Figure 1
Intracellular IFN-γ
expression by 
innate lymphocytes 
in acute ischemic 
stroke.
Intracellular IFN-
expression by V2 T 
cells (A), 
CD3
+
CD56
+
NKT-
like (B) and NK 
(CD3-CD56+) (C) 
and in the peripheral 
blood of acute 
ischemic stroke 
patients within 6 
hours and after 72 
hours from the onset 
of stroke symptoms, 
and those of healthy 
subjects is indicated.
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Cytotoxicity of innate lymphocytess in the acute phase of ischemic stroke 
Perforin expression. Intracellular expression of perforin was analyzed by flow cytometry in 
V2
+
 T cells, CD3
+
CD56
+ 
NKT-like and NK cells (Figure 2). Significantly increased 
percentages of perforin-expressing V2
+
 T cells, NKT-like and NK cells were revealed in 
samples obtained at 72 hours compared to 6 hours after onset of stroke. Perforin expression in 
healthy subjects corresponded to percentages of perforin producing cells at 72 hours of 
patients in all subsets, and differed significantly from percentages at 6 hours in CD3
+
CD56
+ 
NKT-like cells.  
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Figure 2
Intracellular 
perforin expression 
by innate 
lymphocytes in 
acute ischemic 
stroke.  
Intracellular 
perforin expression 
by V2 T cells (A), 
CD3
+
CD56
+
NKT-
like (B) and NK 
(CD3-CD56+) (C) in 
the peripheral blood 
of acute ischemic 
stroke patients 
within 6 hours and 
after 72 hours from 
the onset of stroke 
symptoms, and those 
of healthy subjects is 
indicated. 
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FasL expression. We were also interested in the role of the other major cytotoxic mechanism, 
the Fas/FasL-mediated apoptotic pathway.
28,29,32
 Surface expresion of FasL was examined on 
CD3
+
CD56
+ 
NKT-like cells and NK cells. FasL expression was significantly decreased by 
CD3
+
CD56
+ 
NKT-like and NK cells in samples obtained after 72 hours of symptom onset 
(Figure 3). FasL expression in healthy subjects corresponded to percentages of FasL 
expressing cells at 72 hours of patients in both subsets, and differed significantly from 
percentages at 6 hours in NK cells.  
Figure 3. FasL expression by innate lymphocytes in acute ischemic stroke. Surface FasL 
expression by CD3
+
CD56
+
NKT-like (A) and NK (CD3-CD56+) (B) in the peripheral blood of acute 
ischemic stroke patients within 6 hours and after 72 hours from the onset of stroke symptoms, and 
those of healthy subjects is indicated. HS: healthy subjects, mean±SE is shown. 
NK cytotoxicity. Since we observed significant alterations in expression of mediators of major 
cytotoxic pathways, we analyzed functional changes of NK cytotoxicity in acute ischemic 
stroke. Significantly increased percentages of lysed target cells in samples acquired after 72 
hours of stroke compared to the 6-hour samples were found in each experimental effector-to-
target cell ratio (40:1, 20:1 and 10:1) (Figure 4). 
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Figure 4. NK cell cytotoxicity in acute ischemic stroke. Cytotoxic activity of NK cells as a 
percentage of lysed cells is indicated in ischemic stroke patients within 6 hours and after 72 hours 
from the onset of stroke symptoms, and that of healthy subjects, at different target and effector cell 
ratios. T=target cell, E=effector cell, mean±SE is shown.
DISCUSSION 
Though the nature of immunological changes due to acute ischemic stroke is not fully 
described and understood, they seem to occur rapidly, within hours after the cerebrovascular 
attack. Therefore, in the present study, we analyzed rapid changes in immunological functions 
of innate lymphocytes, which are capable of rapidly producing cytokines influencing 
subsequent adaptive immune responses, and performing cytotoxicity. We particularly focused 
on γδT cells, CD3+CD56+ NKT-like cells and CD3-CD56+ NK cells.  
We found that counts of innate T lymphocytes and NK cells were consistent in the 
acute phase of stroke, and did not differ from control subjects. Similarly, a recent report has 
not found any alterations in NK cell number, only adaptive T lymphocyte subsets showed a 
decreased percentage in stroke.
12
 In contrast to T cells participating in adaptive immune 
responses, number and percentages of innate T lymphocytes were found to be unaltered here. 
However, extensive functional changes of these cell types were revealed. Cell counts and 
percentages do not always reflect faithfully the underlying immunological changes, and 
functional changes may occur without differences of cell counts and percentages even in cell 
subsets with regulatory functions.
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Rapid cytokine production is one of the major mechanisms to influence and regulate 
subsequent immune responses. Therefore, we analyzed pro- and anti-inflammatory cytokine 
expression and production in two different ways: expression of intracellular IFN-γ production 
and anti- and pro-inflammatory cytokine levels in supernatants of isolated innate lymphocyte 
cultures. Intracellular production of IFN-γ was reduced in all lymphocyte subsets, and NK cell 
supernatants showed decreased level of IFN-γ in the hyperacute phase of stroke. Such 
decreased IFN-γ expression and levels normalized by 72 hours. IFN- is a major Th1, pro-
inflammatory cytokine with widespread functions in immune cell regulation, which plays a 
key role in the response to infectious agents.
36,37
 The low IFN- production after stroke 
contributes to acute immunodeficiency in ischemic stroke. Similarly impaired T and NK cell 
responses, particularly a reduced IFN- production were described in a mouse model of focal 
cerebral ischemia.
10
 Of note, production of anti-inflammatory cytokines (IL-4, IL-5, IL-10) 
was not altered in our patients, and expression of inducible co-stimulatory molecule (ICOS) 
connected to Th2 cytokine responses was also normal (data not shown). In a previous study, 
serum levels of IL-10 was normal as well, supporting our data obtained by stimulation of 
isolated innate lymphocytes.
12 
Beside cytokine production, we also examined a major effector pathway, alteration of 
cyotoxicity in the early phase of stroke. The defective cytotoxicity of NK cells within 6 hours 
from onset indicates a rapid loss of immune functions, and provides further evidence for the 
existence of stroke-induced immunodepression in humans. Such early deficiency of 
cytotoxicity correlated well with the decreased production of IFN-γ by NK cells. Since two 
major pathways are responsible for cytotoxicity,
28,29
 we analyzed expression of these 
molecules on Vδ2+ T, NKT-like and NK cells. Interestingly, expression of such mediators 
showed anti-parallel alterations: decrease of intracellular perforin expression after acute 
ischemic stroke correlates with decreased IFN- production in all three innate lymphocyte 
subsets and functional cytotoxicity in NK cells, but apparently not with increase of FasL 
expression in NK and NKT-like cells. However, perforin and FasL represent two different and 
independent mechanisms of cytotoxicity, and the processes of NK cell-mediated necrotic and 
apoptotic cytotoxic pathways mediated by perforin and FasL are differentially regulated by 
cytokines.
38
 Thus expression of perforin and FasL may change inversely and the overall 
cytotoxic effect is a consequence of the two pathways together: early decrease in NK 
cytotoxicity and decreased IFN-γ production and perforin expression by all three subsets was 
characteristic of acute ischemic stroke.  
49
Our data indicate functional impairment of innate lymphocytes in the hyperacute 
phase of stroke. Considering that innate lymphocytes provide acute defense against infections, 
particularly by production of IFN-γ and cytotoxicity, such early deficiency or its disregulated 
normalization may substantially influence susceptibility to infections similar to animal models 
of cerebral ischemia.
10,39
  
Decreased number of T lymphocytes related to adaptive immune responses has 
recently been shown in the hyperacute phase of stroke but functional changes have not been 
addressed.
12
 Here, we show that besides a decreased frequency of adaptive T cells, function of 
innate T lymphocytes and NK cells is also deficient in the early phase of stroke, similarly to 
animal models.
10 
Such functional impairment of innate lymphocytes may complicate the 
reported decreased number of adaptive T lymphocytes in the early phase of stroke and 
contribute to susceptibility to post-stroke infections.
12 
Altogether, our study offers further evidence to support the development of stroke-
induced early immunodepression in humans, suggesting the deficient function of innate 
lymphocytes. These cells may serve as potential new targets in treatments to avoid stroke-
induced immunodepression and its possible consequences, infectious diseases. Controversial 
results of studies where prophylactic antibiotics were administered in the acute and postacute 
phase of stroke
40,41
 highlight the importance of further investigations on the exact, detailed 
pathomechanism of the phenomenon and the search for new therapeutic targets. 
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ABSTRACT
Background: Patients with stroke are more susceptible
to infections, suggesting possible deficiencies of early
immune responses, particularly of leucocytes.
Aims: To serially examine leucocyte antisedimentation
rate (LAR), a simple test to detect activation of
leucocytes, and correlate it with S100b, procalcitonin and
outcome in patients with acute ischaemic events.
Methods: Venous blood samples were taken from 61
healthy volunteers and 49 patients with acute ischaemic
events (acute ischaemic stroke (AIS), n= 38; transient
ischaemic attack (TIA), n= 11) within 6 hours, at 24 and
72 hours after onset of symptoms.
Results: LAR was significantly higher in acute ischaemic
events compared to controls within 6 hours after onset of
stroke regardless of post-stroke infections. In addition, the
increase of LAR was delayed and attenuated in TIA in
contrast to AIS. A deficiency in early increase of LAR was
associated with post-stroke infections and a poor
outcome, measured by the Glasgow Outcome Scale in
AIS. There was a positive correlation between LAR and
S100b at 72 hours after the onset of ischaemic stroke.
Increased levels of S100b at 24 and 72 hours after stroke
were associated with poor outcome.
Conclusions: An early activation of leucocytes indicated
by an increase of LAR is characteristic of acute ischaemic
cerebrovascular events. A delayed and ameliorated
leucocyte activation represented by LAR is characteristic
of TIA in contrast to stroke. Deficient early activation
predisposes to post-stroke infections related to poor
outcome. In addition, the extent of tissue injury correlates
with the magnitude of innate immune responses.
Cerebrovascular diseases of acute onset, including
ischaemic stroke, are associated with diverse
immune responses. The post-ischaemic brain tissue
per se promotes various inflammatory pathways.1 2
In addition, infectious complications have been
frequently reported within the first few days after
stroke, resulting in an increased mortality rate and
worse clinical outcome.3–6 The high incidence of
infections in stroke patients is likely to be a result
of an impaired immune function similar to other
life-threatening conditions.7 8
Leucocytes accumulate in the region of cerebral
ischaemia in the early stage of stroke, within
hours.9 10 The neurological outcome was shown to
be worse and the infarct larger in patients with
severe polymorphonuclear leucocyte accumula-
tion.11 A significant correlation between stroke
volume or stroke severity and an acute increase of
white blood cells (WBC) in the peripheral blood
have been reported.12–14 Increased aggregation of
peripheral leucocytes in the absence of WBC
increase was also reported in major stroke.13
Increased in vitro adhesive properties, activation
of leucocytes indicated by increased plasma oxida-
tion of adrenaline to adrenochrome, and higher
plasma levels of cytokines and proteases have been
shown in ischaemic stroke and transient ischaemic
attack (TIA).15–18 While these studies addressed the
detrimental effect of leucocyte activation, it may
also play a major role in defence against pathogens,
and participate in combating infections. A deficient
activation of leucocytes may thus contribute to an
increased susceptibility to post-stroke infections.
We have recently established a simple test to
examine activation of leucocytes by measuring
upward floating in a tube during one hour of
gravity sedimentation. The leucocyte antisedimen-
tation rate (LAR) indicates the percentage of
leucocytes crossing the middle line of the blood
column upwards during 1 hour of sedimentation.19
It has been shown that a raised LAR is positively
correlated with enhanced leucocyte adherence
proportional to activation, with an increased cell
volume and higher vacuole content of polymorpho-
nuclear leucocytes.20 LAR correlated significantly
with serum procalcitonin (PCT) and C-reactive
protein (CRP) concentration in critically ill
patients with severe sepsis.21 The simple LAR test
was a good positive predictor of bacteraemia in
critically ill patients presenting their first febrile
episode without preceding antibiotic treatment.22 23
Here, we serially examined LAR, S100b and PCT
in patients within hours after onset of acute
ischaemic stroke and TIA to characterise the innate
immune response and its relation to post-stroke
infections. S100b is an astroglial protein, which is
increased in the peripheral blood in patients with
stroke; its peak concentration around day 3 after
stroke correlates with the volume of brain lesions
and clinical outcome.24–29 Increased PCT levels
suggest an infectious origin of fever complicating
an underlying non-infectious febrile disease.30
While the prognostic value of serum PCT concen-
trations is not clear in stroke, its predictive value
for post-stroke infections has been recently impli-
cated.31
MATERIALS AND METHODS
The study protocol was approved by the regional
local ethics committee.
Patients and samples
A total of 49 patients suffering from acute
ischaemic cerebrovascular event and 61 matched
healthy controls were selected for this study. All
patients were admitted to the Department of
Neurology, University of Pecs, Hungary.
Exclusion criteria were infectious diseases, fever
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,4 weeks before stroke, a raised WBC count, erythrocyte
sedimentation rate (ESR), high-sensitivity CRP (hsCRP, cut-off
value ,10 mg/l) and PCT on admission (cut-off value
,0.05 ng/ml), positive chest x ray, haemorrhagic stroke defined
by an acute cranial CT scan, and declining to participate in the
study. Clinical data were collected on admission and at
72 hours; outcome measures were obtained at discharge from
hospital (table 1).
Glasgow Outcome Scale (GOS) at discharge from hospital or
death were used as measures of clinical outcome. Venous blood
samples were taken serially for measurement of LAR, S100b and
PCT within 6 hours after onset of first symptoms (T0), and at
24 (T24) and 72 hours (T72). After 24 hours, patients were
enrolled into a definitive acute ischaemic stroke (AIS) or
transient ischaemic attack (TIA) group based on the persistency
of clinical signs and cranial CT scan. Levels of PCT were
immediately analysed. Blood samples taken for the analysis of
S100b were centrifuged at 3000 g for 10 minutes. Supernatants
were frozen and stored at 280uC until analysis. PCT was
measured by automated fluorescence immunoassay (BRAHMS
Kryptor, B.R.A.H.M.S., Berlin, Germany). Serum levels of S100b
were examined by automated electro-chemiluminescent immu-
noassay (Liaison Sangtec 100 system, DiaSorin, Bromma,
Sweden).
Diagnosis of AIS, TIA and detection of infectious complications
Patients with acute neurological deficits were evaluated by a
certified neurologist within 6 hours of onset of symptoms.
Cranial CT scan was performed acutely to exclude haemor-
rhagic stroke. TIA and definitive stroke were defined according
to international guidelines.32 An evidence-based guideline was
followed to detect infectious complications (in short, physical
and laboratory measures including WBC, ESR, hsCRP, PCT,
fever, abnormal urine, chest x ray or positive cultures).33
Leucocyte antisedimentation rate
LAR was determined as described previously.19 20 In short,
Westergren blood sedimentation rate technique was modified
for measuring leucocyte motion during gravity sedimentation of
the whole blood. After one hour sedimentation, the leucocyte
counts of upper and lower half sections were measured with an
automatic cell counter (Coulter Counter CBC5, Coulter
Electronics, Luton, UK). The formula
LAR=1006(upper2lower)/(upper+lower) was then used to
calculate the percentage of leucocytes that crossed the middle
line of the sedimentation blood column upwards during one
hour of sedimentation (normal range ,10%).
Statistical analysis
Statistical calculations were performed using SPSS 11.0. Student
t test, x2 test, Spearman correlation and Mann–Whitney U test
were used. Data were presented as mean, 95% CI, median and
interquartile range (IQR). A p-value ,0.05 was regarded as
significant.
RESULTS
Clinical data
Based on clinical and neuroimaging data, 38 patients were
categorised into the AIS group and 11 patients into the TIA
group. Eleven of 38 AIS were caused by embolism, either
cardiogenic (n=8) or arterial (n=3). Thirty patients had large
territorial and eight had multiple lacunar infarcts. All but one
patient had an infarct in the anterior circulation. Control CT
showed haemorrhagic transformation in a single case only. Post-
stroke infectious complications occurred only in the AIS group,
with a 10/38 (32%) rate on the 4–5th day as an average (8 cases
with lower airway infection and 2 cases with urinary tract
infection) (table 1). All interventions were done beyond 48
hours, except in one patient (bladder catheter in 7, nasogastric
tube in 10, artificial ventilation in 5 patients).
Serial measurement of LAR in acute ischaemic stroke and TIA
LAR indicating activation of leucocytes was measured on
admission within 6 hours, and at 24 and 72 hours after onset
of stroke. LAR on admission was significantly higher in patients
with acute ischaemic events, ie AIS and TIA, compared to
healthy controls (AIS, median 0.342, IQR 0.229–0.426; TIA,
median 0.14, IQR 0.069–0.182; vs control, median 0.060, IQR
0.024–0.088; p,0.001, p=0.007, respectively) (fig 1A). In
addition, LAR was significantly higher at T0 and T72 in
patients with definitive stroke compared to patients with TIA
(T0, AIS, median 0.342, IQR 0.229–0.426, vs TIA, 0.14, 0.069–
0.182, p=0.008; T72, AIS, median 0.463, IQR 0.264–0.552, vs
TIA, median 0.255, IQR 0.147–0.388, p=0.012) (fig 1B). To
exclude the possibility that post-stroke infections in AIS were
responsible for the early difference between the two subgroups,
TIA was also compared to AIS without post-stroke infections
(n=28). Difference in median LAR at T0 remained significantly
higher in the AIS group without post-stroke infections (median
0.338, IQR 0.240–0.406 vs 0.14, 0.069–0.182, p=0.01) (fig 2A).
Of note, no differences in WBC and serum levels of PCT on
admission were observed when AIS and controls, or AIS and
TIA were compared to each other; ESR also did not indicate
infections (table 1).
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Table 1 Demographic and clinical data of subjects
Acute cerebrovascular event (n= 49)
Control (n= 61) p ValueAIS (n=38) TIA (n=11)
GOS at discharge* 3.1 (2.6–3.5) 4.3 (3.6–4.9) NA 0.006
Length of stay (day)* 8.4 (6.7–10.2) 5.9 (4.0–7.8) NA NS
Infection rate{ 10/38 0/11 NA ,0.001
Onset of infection (day)* 4.3 (3.47–5.13) NA NA NA
PCT on admission (ng/ml)* 0.09 (0.06–0.11) 0.06 (0.02–0.09) ,0.05 NS
WBC count on admission (g/l)* 8.2 (7.3–9.1) 7.4 (6.6–8.1) 7.8 (7.3–8.4) NS
*Median and interquartile range, comparisons by Mann-Whitney U test.
{x
2
test.
AIS, acute ischaemic stroke; TIA, transient ischaemic attack; GOS, Glasgow Outcome Scale; WBC, white blood cell; PCT,
procalcitonin; NA, not applicable; NS, not significant.
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Serial measurement of LAR in patients with post-stroke infection
and poor outcome
When LAR was serially analysed (T0, T24 and T72) in 38
patients with AIS, a continuous increase of LAR was observed
(fig 1B). However, when patients with post-stroke infections
were separately examined, a significant decrease of LAR was
observed at 24 hours compared to AIS without infectious
complications (p=0.028) (fig 2A). Similar although non-
significant reduction was also observed at 72 hours. These data
may suggest that a deficient increase of LAR could be related to
an increased risk of post-stroke infection due to a dysregulated
activation of leucocytes. Therefore, we examined whether LAR,
indicating activation of leucocytes, is related to the outcome of
stroke measured by GOS, and compared AIS patients with poor
and favourable outcome. AIS patients with favourable outcome
had significantly higher LAR24 (median 0.436, IQR 0.273–0.531
vs median 0.262, IQR 0.236–0.312, p=0.02) (fig 2B); the mean
value of GOS in patients with post-stroke infections was
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Figure 1 Leucocyte antisedimentation rate (LAR) in healthy controls,
patients with transient ischaemic attack (TIA) and ischaemic stroke. (A)
LAR measured at 6 hours after onset of symptoms in patients with
definitive ischaemic stroke, TIA and healthy controls. LAR (median,
interquartile range, minimum–maximum) was measured on admission,
within 6 hours after onset of clinical symptoms in 38 patients with
definitive ischaemic stroke, 11 patients with TIA and 61 healthy
volunteers. Definitive stroke and TIA were determined retrospectively
after 24 hours based on clinical and neuroimaging findings (Mann–
Whitney U test was used). (B) Serial examination of LAR in patients with
TIA and ischaemic stroke. LAR (median, interquartile range, minimum–
maximum) was measured on admission (T0), at 24 hours (T24) and
72 hours (T72) after onset of symptoms in 38 patients with acute
ischaemic stroke without infectious complications and in 11 patients
with TIA (Mann–Whitney U test was used).
Figure 2 Leucocyte antisedimentation rate (LAR) in patients with
ischaemic stroke related to post-stroke infections and clinical outcome.
(A) Serial examination of LAR comparing patients with definitive stroke
with and without post-stroke infections. LAR (median, interquartile
range, minimum–maximum) was measured on admission (T0), at
24 hours (T24) and 72 hours (T72) after onset of symptoms in 28 stroke
patients without post-stroke infection and 10 patients with infectious
complications (Mann–Whitney U test was used). (B) Comparison of LAR
measured at T24 in patients with good and poor outcome after definitive
ischaemic stroke. LAR (median, interquartile range, minimum–maximum)
was examined in 38 patients measured at 24 hours after acute
ischaemic stroke in good (GOS.3) versus poor (GOS(3) outcome
defined by Glasgow Outcome Scale at hospital discharge (Mann–
Whitney U test was used). (C) Clinical outcome of patients with acute
ischaemic stroke. Glasgow Outcome Scale (GOS, mean, 95% CI)
obtained at discharge from hospital or death in 28 patients without
infection compared to 10 patients with infection after acute ischaemic
stroke (Student t test, p,0.001).
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significantly lower (p,0.001), indicating a poor outcome
(fig 2C).
Relation of LAR to S100b
An important marker of stroke outcome is S100b, which is also
related to the extent of infarct.24–29 Median S100b was
significantly higher among patients with definitive stroke at
24 hours (median 0.218, IQR 0.09–0.75, p=0.001) and 72 hours
(median 0.228, IQR 0.075–1.035, p=0.002) compared to S100b
on admission (median 0.10, IQR 0.06–0.22), but was not
increased in patients with TIA. In addition, serum S100b
protein at T24 and T72 was significantly higher in AIS patients
with poor outcome (GOS(3) compared to good outcome
(GOS.3) (T24, median 0.393, IQR 0.13–1.69 vs median 0.121,
IQR 0.08–0.24, p=0.01; T72, median 1.35, IQR 0.20–2.01 vs
median 0.136, IQR 0.06–0.27, p=0.014, respectively) (fig 3A).
When LAR and serum levels of S100bwere compared in patients
with definitive stroke, a weak, but positive correlation was
found on the 3rd post-stroke day (regression analysis with a
Spearman rank correlation coefficient of r=0.457, p,0.05)
(fig 3B). These data may indicate that increased levels of S100b
correlate with high LAR at T72, suggesting that bigger extent of
infarct may be related to increased activation of leucocytes.
DISCUSSION
LAR was previously reported in the critical care setting as a
novel method for detecting activation of circulating leucocytes
that can be the earliest sign of systemic inflammatory response
syndrome.22 Here, we found that an early activation of
leucocytes occurs during acute cerebrovascular events, since
patients with both definitive stroke and TIA had significantly
higher LAR compared to healthy controls as early as 6 hours
after the onset of symptoms. In addition, the increase of LAR
was proportional to the extension of brain damage: first, LAR
was significantly higher in individuals with definitive stroke
compared to TIA within 6 hours after onset of symptoms; in
addition, measured on the third post-stroke day, LAR correlated
with serum levels of S100b, a marker of infarction size.24–29
Indeed, a possible association between leucocyte activation
within the brain and stroke volume has been shown pre-
viously.11 In the peripheral blood, association between leucocyte
aggregation and infarct size has also been shown, similar to our
data.13 Despite the functional abnormalities, we did not find an
increase of WBCs. A similar alteration of leucocyte functions
without any change in number has been reported, but increased
leucocytes has also been found in the acute phase of stroke.12–16
In the TIA group, we detected a significant increase of LAR
compared to healthy controls, but this was delayed and
attenuated compared to AIS. We considered the possibility that
infectious complications in the AIS group might be responsible
for the difference between TIA and AIS. However, such early
activation of leucocytes was unlikely to be related to infections
4 days later in AIS. Indeed, when patients with post-stroke
infections were excluded from the AIS group, the early
difference regarding LAR still remained significant between
AIS and TIA. Thus, an early activation of leucocytes represented
by an increase of LAR within 6 hours after onset of stroke was
ameliorated in TIA compared to AIS regardless of post-stroke
infections.
Previous reports emphasised the detrimental effect of
leucocyte activation in stroke, supported by the association
between infarct size and leucocyte infiltration in the ischaemic
tissue.10 11 Accordingly, the magnitude of the increase of LAR
also correlated with serum concentration of S100b. However,
activation of leucocytes in the systemic circulation may also
reflect the mobilisation of innate immune responses following
tissue damage, which may serve to combat infections by
mounting a pro-inflammatory response. Ideally, a delicate
balance between detrimental and beneficial effects of early
innate immune responses should be required to reduce tissue
damage but also fight infections in the acute phase of stroke.34
In our cohort, a progressive increase of LAR was detected within
the first 72 post-stroke hours if patients with post-stroke
infections were excluded from the analysis. In contrast, a
deficient increase of LAR at 24 hours was found in those
patients, who became febrile on the 4th–5th days with apparent
clinical and laboratory signs of either respiratory or urinary tract
infections. A similar, but non-significant defect in the increase
of LAR was also seen at 72 hours. This may refer to a
dysregulated activation of leucocytes providing insufficient
barrier to bacterial infections.
Although PCT was measured serially in order to detect early
infections in our cohorts, we also analysed its relation to
definitive stroke, TIA, LAR and S100b, since PCT has been
proposed as an indicator of systemic inflammatory response in
non-infectious situations.35 36 We did not find any difference in
PCT levels measured at 6, 24 and 72 hours after stroke in any
subgroup analyses, except that a slight increase of PCT at
72 hours indicated subsequent post-stroke infections. Similar
data regarding PCT have been reported by others.31
In summary, although the number of recruited patients is
relatively small, our pilot prospective study suggests several
important messages: (1) activation of leucocytes represented by
increase in LAR happens within hours after ischaemic stroke; (2)
although LAR was increased in TIA compared to healthy
subjects, it was delayed and ameliorated compared to definitive
ischaemic stroke; (3) decreased activation of leucocytes reflected
by a deficient increase of LAR may predispose to post-stroke
infections and predict worse outcome; and (4) a positive
correlation exists between LAR and S100b on the third post-
stroke day, indicating a relationship between extent of infarct
and innate immune responses. <
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Figure 3 Correlations of S100b with outcome measures and leucocyte
antisedimentation rate (LAR). (A) Comparison of serum S100b in
patients with poor and good outcome after definitive ischaemic stroke.
Plasma S100b protein concentrations (median, interquartile range,
minimum–maximum) were examined in 38 patients measured on
admission (T0), at 24 hours (T24) and 72 hours (T72) after acute
ischaemic stroke in good (GOS.3) versus poor (GOS(3) outcome
defined by Glasgow Outcome Scale at hospital discharge (Mann–
Whitney U test was used). (B) Association between LAR and S100b
measured at 72 hours after onset of symptoms in patients with definitive
stroke. Scatterplot of serum S100b level versus LAR measured at T72
was created in 38 patients after acute ischaemic stroke. A regression
analysis with a Spearman rank correlation coefficient of r= 0.457
(p,0.05) is shown.
Take-home messages
c Within hours of ischaemic stroke systemic activation of
leucocytes occurs.
c The magnitude and sequence of activation depends on
whether stroke is transient or definitive.
c Activation of leucocytes positively correlates with the size of
infarct.
c Deficient activation predisposes to post-stroke infection and
poor outcome.
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Multiple sclerosis and the CTLA4 autoimmunity 
polymorphism CT60: no association in patients 
from Germany, Hungary and Poland
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Polymorphisms in the CTLA4 gene region have been associated with susceptibility to autoimmune
diseases. The recently described single nucleotide polymorphism CT60, located in the 39 untranslated
region of CTLA4 is associated with Graves’ disease, thyroiditis, autoimmune diabetes and other
autoimmune diseases. A case-control association study was conducted in German, Hungarian and
Polish multiple sclerosis (MS) patients and regional control individuals for the CTLA4 CT60 and
149A/G polymorphisms. No significant association of these polymorphisms or respective haplotypes
with MS was found. No association of CT60 genotypes with T cell expression of ICOS and CTLA-4
after in vitro stimulation was detected. Multiple Sclerosis 2008; 14: 153–158. http://msj.sagepub.com
Key words: association; CTLA-4; genetics; multiple sclerosis; polymorphism
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Introduction
Multiple sclerosis (MS) is a complex genetic disease in
which susceptibility and resistance alleles determine
the individual threshold for developing overt
autoimmune disease (AID) [1]. These polymorphisms
may be common variants and overlap between
species and different AID. Prime candidates for
shared autoimmunity genes are the MHC, PTPN22
and CTLA4 [2]. The CTLA4 region has been mapped
as a susceptibility region in mice (Idd5.1) and men
(IDDM12) for various AID. Idd5.1 influences both
experimental autoimmune encephalomyelitis (EAE)
and diabetes in mice in an opposite way and is
associated with differential expression of inducible
costimulator (ICOS) and a murine splice variant of
cytoxic T-lymphocyte-associated antigen-4 (CTLA-4)
(ligand-independent [li]CTLA-4) [3–5]. In humans, a
polymorphism in the 39UTR of CTLA4 (CT60) has
been shown to be associated with Graves’ disease,
autoimmune thyroiditis, diabetes and genotype-
dependent regulation of a CTLA-4 splice variant
(soluble [s]CTLA-4) [6]. Since then, association of the
CT60*G allele with various AID has been reported (as
examples [7–13]).
Polymorphisms in the CD28/CTLA4/ICOS gene
cluster have been subject of intense investigation for
association with MS. Lorentzen et al. found no asso-
ciation with MS across the CD28/CTLA-4/ICOS gene
region [14]. In another study, two markers in the
CTLA-4 gene region among 17 tested within 2q33
showed some weak association in Finnish MS fami-
lies [15]. Recently, association of ICOS haplotypes
with IL10-secretion and relapsing–remitting MS has
© 2008 SAGE Publications 10.1177/135248507082357
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been reported [16]. Among other polymorphisms of
CTLA4, the 2318 C/T, 149A/G and (AT)n repeat and
their respective haplotypes have been intensely inves-
tigated showing inconsistent results so far (for com-
bined analyses [17–19] and detailed overview [20]).
No association of MS with CT60 has been
reported so far in Australian, Norwegian and British
patients [14,19,21]. However, in MS patients from
Flanders, association with the 149A/G*G-CT60*G
haplotype has been reported [20] and recently an
association of the CT60*G allele with MS was
detected in multicase MS families with a history of
other autoimmune diseases [22].
In the present study a possible association of
CT60 with MS in patients from Germany, Hungary
and Poland was investigated. Although the
CT60*G/G genotype was consistently overrepre-
sented in MS patients, no significant association was
found. No genotype-dependent regulation of ICOS
and CTLA-4 expression was detected.
Patients and methods
Patients
German MS patients were recruited at the
Neurology Department, University of Tübingen.
German controls were recruited from age and sex-
matched participants of the Dortmund Health
Study, a health survey of the general population in
the west and from participants of the MEMO-Study
(Memory and Morbidity in Augsburg Elderly) con-
ducted in the south of Germany [23] as well as indi-
viduals from the Tübingen region. Polish MS patients
were recruited at the Department of Neurology,
Medical University of Lodz. Hungarian MS patients
were recruited from the Department of Neurology,
University of Pecs and Jahn Ferenc Teaching
Hospital, Budapest. All patients were confirmed MS
patients according to the Poser or McDonald crite-
ria [24,25]. The study was approved by the local
Ethics committees and patients gave informed
consent prior to inclusion.
Genotyping
The CT60 SNP was genotyped by the pyrosequenc-
ing method [26] on a PSQTM 96MA System (Biotage
AB, Uppsala, Sweden) and the 149A/G SNP was
genotyped using a melting-curve-based analysis on
a Light cycler® 480 system (Roche Diagnostics,
Basel, Switzerland), according to the manufacturer’s
protocol. DR2 typing was performed by PCR using
DRB1*15/16-specific primers [http://www.ihwg.
org/protocols/sbt/sbtprot.htm, chapter 10-A]. All
nucleotide sequences are available upon request
from the corresponding author.
ICOS and CTLA-4 expression analysis
Whole blood was subjected to density gradient
separation as described previously [27]. Periphal
blood mononuclear (PBMC) were incubated at
5 3 106 cells per well in 24-well plates in 2 ml RPMI
1640 cell medium supplemented with 10% FCS, L-
glutamine and penicillin/streptomycin, containing
5 mg/ml PHA for up to 48 h. Cells were stained with
the following antibodies: anti-CD4-FITC, anti-
ICOS-PE, anti CTLA-4-PE and the respective isotype
controls (all from BD Pharmingen). Prior to CTLA-4
staining, cells were fixed and permeabilized
(Cytofix/Cytoperm, BD Pharmingen, Franklin
Lakes, NJ, USA). Dead cells were excluded after
staining with 7-amino-actinomycin D (7-AAD).
Flow cytometry was performed on a FACSsort (BD
Biosciences, Mountain View, CA, USA) and data
were analysed using FlowJo software (TreeStar, San
Carlos CA, USA). Delta Mean fluorescence intensity
(deltaMFI) was calculated as MFI (antibody) – MFI 
(respective isotype control).
Statistical analysis
Statistical analysis was performed using the JMP5
software package (SAS Institute, Cary, NC, USA). For
haplotype analysis the Haploview software was 
used [28]. For meta-analysis the RevMan software
(Version 4.2 for Windows. Copenhagen: The Nordic
Cochrane Centre, The Cochrane Collaboration,
2003) was employed. x2 test was used to test for
Hardy-Weinberg equilibrium.
Results
Association of the CT60 and 149A/G 
polymorphism with MS
In all populations, genotype counts did not deviate
significantly from those expected under Hardy-
Weinberg equilibrium for both SNPs.
No differences were found between genotypes
and allele frequencies when patients and control
individuals were compared within our three popu-
lations (Table 1). Since numbers of patients and
control persons as well as allele frequencies differed
substantially among populations, a population-
stratified meta-analysis rather than pooling the
samples for a combined analysis was performed.
This meta-analysis showed no association of MS
with CT60 or 149A/G allele frequencies but an
overrepresentation of the CT60*G/G genotype
among MS patients from all three populations.
However, this finding did not reach statistical sig-
nificance (meta-analysis in 621 MS patients and
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Table 1 Genotype and allele frequencies among German, Hungarian and Polish MS patients
and control persons for the 149A/G and CT60 SNP
149AG n A/A A/G G/G A G
Germany MS 200 0.38 0.45 0.18 0.60 0.40
controls 469 0.38 0.46 0.15 0.62 0.38
Hungary MS 193 0.33 0.50 0.17 0.58 0.42
controls 91 0.35 0.53 0.12 0.62 0.38
Poland MS 180 0.33 0.53 0.14 0.60 0.40
controls 171 0.29 0.53 0.19 0.55 0.45
CT60 n G/G A/G A/A G A
Germany MS 227 0.31 0.52 0.17 0.57 0.43
controls 473 0.31 0.49 0.20 0.55 0.45
Hungary MS 206 0.37 0.47 0.16 0.61 0.39
controls 141 0.30 0.57 0.12 0.59 0.41
Poland MS 188 0.40 0.45 0.15 0.63 0.37
controls 190 0.37 0.55 0.08 0.65 0.35
804 controls, odds ratio (OR) for the CT60*G/G
genotype 1.13 [95% CI 0.90–1.42]).
Genotype frequencies were then included
among MS patients and controls extracted or calcu-
lated from two previously published case-control
association studies [14,19] into a meta-analysis.
Combining these published data with the present
data allowing the analysis of 1228 MS patients and
1440 controls, the OR was 1.12 [95% CI 0.95–1.31]
for the association of the CT60*G/G genotype with
MS (Figure 1). Previously published family-based
linkage studies were not included into this analysis.
Stratification of our genotype data for DR2 revealed
an overrepresentation of the CT60*G/G genotype
in both DR21 patients and control individuals
from Hungary and Poland (data not shown).
For haplotype association analysis only patients
with known genotypes at both polymorphisms
were included. No association with 149A/G-CT60
Figure 1 Meta-analysis for the CT60*G/G genotype of two previously published case-control association studies in Australian
and Norwegian MS patients and data from German, Hungarian and Polish patients. Data from previously published 
family-based linkage studies are not incorporated. agenotype numbers were calculated by multiplying published genotype
frequencies and numbers of MS patients and controls, respectively.
haplotypes was detected, even after stratification of
patients for DR2 (Table 2 and data not shown).
Information about the disease course was avail-
able in 528 patients (relapsing–remitting 67.0%,
secondary-progressive 23.5%, primary-progressive
9.5%) and about disease progression (onset, disease
duration, EDSS scores) in 435 German and
Hungarian MS patients. No association of geno-
types with age of onset, progression and disease
course was found in these patients.
CT60 genotype-dependent expression 
of co-stimulatory molecules
CT60 genotype-dependent expression of sCTLA4
has been reported previously [6] and the mouse
orthologous Idd5.1 region is associated with differ-
ential surface expression of ICOS [4]. ICOS and
CTLA-4 expression in CD41 T cells of healthy indi-
viduals with known CT60 genotypes by flow cytom-
etry was analysed. No significant differences were
found in expression levels of these molecules ex vivo
or after 24 and 48 h of in vitro stimulation (Figure 2).
Discussion
CTLA4 is a prime candidate for a shared autoimmune
gene [2], and a recently described polymorphism in
the 39UTR of CTLA4, CT60, has been shown to be
associated with different autoimmune diseases
[6–13]. These observations are consistent with find-
ings in the respective mouse models showing the
association of the orthologous Idd5.1 locus with
autoimmune diabetes and EAE [4,29]. No consis-
tent association of CTLA4 with MS has been
described so far and recent publications including
genotyping data of CT60 have been negative
[14,19,21] except for one study demonstrating the
149A/G*G-CT60*G haplotype being associated
with MS [20] and another demonstrating an associ-
ation of CT60*G with MS in multicase MS families
with a history of other autoimmune diseases [22].
In the present study, including MS patients from
three different European populations, a significant
effect of this polymorphism on susceptibility to MS
or association with different disease courses, disease
progression and onset of disease could not be
demonstrated. A slight overrepresentation of the
CT60*G/G genotype among MS patients was found,
including all three populations and two previously
published association studies, totaling 1228 MS
patients and 1440 controls, into a meta-analysis.
In German, but not Hungarian or Polish MS
patients, the frequency of the 149A/G*G-CT60*G
haplotype was slightly higher compared with con-
trol persons, while a reverse pattern was found for
the 149A/G*A-CT60*G haplotype. This correlates in
part with the observation by Suppiah et al. [20]; how-
ever, our findings were not statistically significant.
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Table 2 149A/G-CT60 haplotype frequencies among German,
Hungarian and Polish MS patients and control persons
n Frequency
MS/controls Haplotype MS Controls
Germay 200/416 AA 0.417 0.408
GG 0.389 0.340
AG 0.186 0.214
GA 0.008 0.038
Hungary 170/90 GG 0.384 0.383
AA 0.361 0.366
AG 0.227 0.245
GA 0.028 0.006
Poland 178/171 GG 0.398 0.443
AA 0.372 0.344
AG 0.226 0.206
GA 0.004 0.007
Except for the GA haplotype in German MS patients and controls
(x2 5 8.7; P 5 0.0031) no significant differences were detected.
Figure 2 Expression of ICOS and CTLA-4 on CD41 T cells. PBMC were isolated and stimulated as described in the Methods
section. (A) ICOS and CTLA-4 expression ex vivo and after 48-h stimulation with PHA. Shown are histograms of cells gated on
CD417-AAD2 cells; grey line: isotype control, black line: anti-ICOS or anti-CTLA-4, respectively. (B) ICOS and CTLA-4 expres-
sion on CD41 cells of individuals with different CT60 genotypes, ex vivo and after 24 h or 48 h of stimulation with PHA in vitro.
Data are mean delta MFI, SEM indicated (total n 5 4 for each the G/G and A/G genotype n 5 3 for the A/A genotype). No
significant expression differences between individuals with different genotypes were found by ANOVA.
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This might be due to differences in the respective
study-populations. Furthermore, a family-based
study might be more powerful than the present case-
control approach to detect a weakly MS-associated
haplotype [30].
Also, selection of a MS-subphenotype, defined
by the presence of a family history of other autoim-
mune diseases and MS, seems to increase the power
to detect an underlying common autoimmune-
polymorphism, as demonstrated by Barcellos et al.
[22]. The present study did not stratify the study
population for such a subphenotype.
On the other hand, our negative findings regard-
ing the 149A/G polymorphism match well with a
meta-analysis on previously published studies
examining this polymorphism in MS patients,
showing no association in 2453 MS patients and
1851 control persons [19]. CT60 genotype-depend-
ent variation of mRNA levels of the sCTLA-4 splice
variant has been shown previously [6]. However,
these findings have been challenged later [31–33],
showing no genotype-dependent differences in
mRNA and protein levels of sCTLA. It has been
shown that the orthologous mouse locus Idd5.1
regulates ICOS expression on T cells in C57BL/10
congenic NOD mice [4]. Expression levels of a
mouse-specific CTLA-4 splice variant (li-CTLA-4)
are also dependent on genetic variation in this
region [5]. Genotype-dependent expression differ-
ences were not found for ICOS and CTLA-4 in
healthy individuals with known CT60 genotype.
In summary, it was not possible to demonstrate
an association of this common autoimmune poly-
morphism with multiple sclerosis. However, this
does not rule out a possible weak association, espe-
cially in a subpopulation of patients with an under-
lying autoimmune-prone genetic background.
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Abstract
The interleukin (IL) -23/IL-17 cytokine axis has been suggested to play an important role in the development of several autoimmune diseases
including multiple sclerosis. Here, we compared the prevalence of C2370A single nucleotide polymorphism (SNP) in the 3′ untranslated region
(3′UTR) of the IL-23 receptor (IL23R) between 223 patients with relapsing-remitting multiple sclerosis (RRMS) and 200 healthy controls.
The A2370A genotype was significantly over-represented among patients with RRMS (10.8%) and RRMS exhibiting oligoclonal bands in the
cerebrospinal fluid (12.9%) when compared to healthy subjects (5.50%). Multiple regression analysis revealed that presence of AA genotype
provides a two-fold risk for the development of multiple sclerosis (OR= 2.072, 95% CI: 0.988–4.347, p< 0.05). These data indicate that IL23R
represents a novel shared susceptibility gene as its association with inflammatory bowel disease (IBD) has recently been verified.
© 2007 Elsevier Ireland Ltd. All rights reserved.
Keywords: Multiple sclerosis; IL-23; IL23R; IL-17; Shared autoimmunity gene
Cytokines play an important role in the initiation and mainte-
nance of autoimmune diseases. Previous data emphasized the
importance of IL-12 driving differentiation of naı̈ve T cells into
IFN-g producing Th1 cells essential for cell-mediated immu-
nity [4]. Since targetingmolecules of the IFN-g pathway inmice
resulted in more severe autoimmune diseases, additional inflam-
matory cytokines, particularly IL-23 and IL-17 have recently
been suggested to play an important role in the establishment
of autoimmune diseases [7,11]. One of the Th17 differentia-
tion pathways is IL-23-dependent and IL-23 is necessary for
the survival and expansion of Th17 cells; this effect is medi-
ated through the IL23R signaling pathway [6]. A genome-wide
association study has recently identified several polymorphisms
in the IL23R gene associated with inflammatory bowel disease
(IBD). The C2370A allele in the 3′UTR showed one of the most
significant associations with IBD [2]. Here, we examined the
association of this SNP with multiple sclerosis.
∗ Corresponding author. Tel.: +36 72 535 900; fax: +36 72 535 911.
E-mail address: zsolt.illes@aok.pte.hu (Z. Illes).
Patients: MS patients were recruited at the Department of
Neurology, University of Pecs and at Jahn Ferenc Teaching
Hospital, Budapest, Hungary. All patients were confirmed MS
patients according to McDonald’s criteria [10]. Patients gave
informed consent prior to inclusion, approved by the local ethics
committee of University of Pecs. Altogether, 223 patients with
relapsing-remitting MS were involved in the study (61 males,
162 females, mean age 41.1± 0.71 years). Forty-five patients
have progressed into a secondary progressive phase follow-
ing a relapsing-remitting course. Cerebrospinal fluid (CSF) was
examined in 97 cases and 87.6% was positive for oligoclonal
bands (OCB) determined by isoelectric focusing. The control
population consisted of 200 clinically healthy subjects (110
males, 90 females, mean age 38.7± 0.81 years). None of the
patients including those with predominantly optic and spinal
cord symptoms (OS-MS) had Devic’s disease according to the
recently proposed criteria [14].
Genotyping: Genomic DNA was extracted from peripheral
blood leukocytes with a routine salting out method. For the
amplification of the target sequence the following primers were
designed and used: 5′-ATCGTGAATGAGGAGTTGCC-3′ as
0304-3940/$ – see front matter © 2007 Elsevier Ireland Ltd. All rights reserved.
doi:10.1016/j.neulet.2007.11.015
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the sense and 5′-TGTGCCTGTATGTGTGACCA-3′ as the anti-
sense primer. Digestion by MnlI restriction endonuclease was
used to determine C2370A (CA), C2370C (CC), and A2370A
(AA) genotypes. Genotyping for HLA-DRB1*1501 was done
in 216 cases (Olerup HLA SSP, GenoVision, Qiagen).
Statistics: Statistical analysis was carried out using Excel
and SPSS 11.5 for Windows. We performed chi-square tests
and regression analyses to uncover the associations between the
SNP and MS. Odds ratios were calculated with 95% confidence
intervals (95% CIs). All p-values refer to a two-sided test and
p< 0.05 was considered significant. The examined parameters
were the following: sex, disease subtype (relapsing-remitting
and secondary progressive), presence of oligoclonal bands and
carrying the HLA-DRB1*1501 susceptibility allele.
Genotyping data were in Hardy–Weinberg Equilibrium for
C2370A SNP tested for Hungarian individuals. The AA geno-
type was significantly over-represented in the 223 MS patients
compared to 200 healthy controls (10.8% vs. 5.50%, p< 0.05)
(Table 1). Multiple regression analysis revealed that presence of
AA genotype provides a two-fold risk for the development of
multiple sclerosis (OR= 2.072, 95% CI: 0.988–4.347, p< 0.05).
TheAAgenotypewas also significantly over-represented among
patients exhibiting OCB in the CSF (n= 85) compared to HS
(12.9% vs. 5.50%, p< 0.05). Multiple regression analysis indi-
cated a two-fold risk for the presence of oligoclonal bands in the
CSF (OR= 2.554, p= 0.03). No such differences were observed
whenHLA-DR15-positive (n= 84) (10.7%vs. 5.50%,p= 0.117)
or negative (n= 132) (11.4% vs. 5.50%, p= 0.052) subgroups
were separated and compared to healthy subjects, respectively.
In addition, the A allele frequencywas not significantly different
betweenMS patients and control individuals (31.2% vs. 29.8%).
Nor did we find any significant differences when female patients
(n= 162) were separately analyzed. Although the sample size
was small (n= 45), no association was found with secondary
progressive disease course.
Our data indicate that a genetic association exists between
relapsing-remitting MS and the C2370A polymorphism of the
IL23R gene. The susceptible genotype provides a two-fold risk
for developing multiple sclerosis. This polymorphism was also
associatedwith patients exhibiting oligoclonal bands in the CSF.
The susceptibility was independent from HLA-DRB1*1501
positivity indicating that cytokine responses rather than presen-
tation of certain autoantigens might be affected.
The IL-23/IL-17 axis has already been suggested to play an
important role in MS. The number of IL-17 mRNA expressing
Table 1
Prevalence of the 3′UTR C2370A single nucleotide polymorphism of the IL-23
receptor gene in MS patients and healthy controls
3′UTR C2370A
SNP genotypes
Multiple sclerosis (n= 223) Controls (n= 200)
CC 108 (48.4%) 92 (46.0%)
CA 91 (40.8%) 97 (48.5%)
AA 24 (10.8%)* 11 (5.50%)*
A allele frequency 31.2% 29.8%
* p< 0.05.
mononuclear cells is increased in MS, especially in relapse and
within the CSF [9]. Accordingly, elevated IL-17 transcripts have
been reported in MS plaques [8]. Recent data also indicated
an elevated secretion of IL-23 by dendritic cells (DC) and an
increased IL-17 production by T cells from MS patients, which
could be modulated to result in IL-10 production by DC [13].
IL-17 levels in theCSFhad significant correlationwith higher
CSF/serum albumin ratio suggesting the role of IL-17 in the
destruction of the blood–brain barrier [5]. Since IL-23 is nec-
essary for the survival and expansion of Th17 cells mediated
through the IL23R signaling pathway [6], we examined whether
blood–brain barrier damage might be associated with IL23R
polymorphism. The AA genotype was not associated with high
CSF/serum albumin ratio in RR-MS, although it was signifi-
cantly over-represented in our patients with OCB in the CSF. In
addition, in patients with opticospinal MS (OS-MS), IL-17 lev-
els were significantly increased in the CSF [5]. However, none
of our 20 RR-MS patients with predominant opticospinal symp-
toms incompatiblewith the diagnostic criteria of Devic’s disease
exhibited an AA genotype, while CC and CA genotypes were
equally represented [14].
Since association of theA2370Agenotypewith inflammatory
bowel disease has recently been reported, our data also suggest
that IL23R may represent a novel common autoimmunity gene
shared by several distinct disorders, particularlyMSand IBD[2].
Indeed, the A2370A genotype has been very recently shown to
be associated with an increased risk for rheumatoid arthritis and
psoriasis [1,3,12]. However, no association was found with scle-
roderma and SLE, suggesting that this particular polymorphism
may be associated with diseases mediated by cellular rather than
humoral immune responses [3,12].
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Abstract
To identify the molecular network of the genes deregulated in multiple sclerosis (MS), we studied gene expression profile of purified CD3+
T cells isolated from Hungarian monozygotic MS twins by DNA microarray analysis. By comparing three concordant and one discordant pairs,
we identified 20 differentially expressed genes (DEG) between the MS patient and the genetically identical healthy subject. Molecular network
of 20 DEG analyzed by KeyMolnet, a comprehensive information platform, indicated the close relationship with transcriptional regulation by
the Ets transcription factor family and the nuclear factor NF-kB. This novel bioinformatic approach proposes the logical hypothesis that aberrant
regulation of the complex transcriptional regulatory network contributes to development of pathogenic T cells in MS.
© 2007 Elsevier Ireland Ltd. All rights reserved.
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Multiple sclerosis (MS) is an inflammatory demyelinating dis-
ease mediated by an autoimmune process that is triggered by
a complex interplay of both genetic and environmental factors.
MS twin studies showed that the concordance rate for monozy-
gotic (MZ) twins is approximately 30%, while it is less than 5%
for dizygotic (DZ) twins, suggesting the possible involvement
of not a single but multiple susceptibility genes in development
of MS [13]. However, most of the candidate genes reported
previously have not well been validated. Because regulation of
gene expression is controlled through the combinatorial action
ofmultiple transcription factors that activate or repress transcrip-
tion via binding to cis-regulatory elements of target genes, the
gene network analysis is more important to clarify the complex
autoimmune process underlying the pathogenesis of MS.
DNA microarray technology is an innovative approach that
allows us to systematically monitor the expression of thousands
∗ Corresponding author at: Department of Bioinformatics, Meiji Pharmaceu-
tical University, 2-522-1 Noshio, Kiyose, Tokyo 204-8588, Japan.
Tel.: +81 42 495 8678; fax: +81 42 495 8678.
E-mail address: satoj@my-pharm.ac.jp (J.-i. Satoh).
of genes in disease-affected tissues and cells. The compre-
hensive gene expression profiling has given new insights into
molecular mechanisms promoting the autoimmune process in
MS [19]. By using this technology, we recently showed that
interferon-beta (IFNb) treatment elevates the expression of a
set of IFN-responsive genes in highly purified peripheral blood
CD3+ T cells of relapsing-remitting MS patients [6]. IFNb
immediately induces a burst of gene expression of proinflamma-
tory chemokines with potential relevance to IFNb-related early
adverse effects inMS [17]. T-cell gene expression profiling clas-
sifies a heterogeneous population of Japanese MS patients into
four distinct subgroups that differ in the disease activity and
therapeutic response to IFNb [16]. The majority of differen-
tially expressed genes in T cells between untreated MS patients
and healthy subjects were categorized into apoptosis signaling
regulators [15]. However, we could not exclude the possibil-
ity that the heterogeneous genetic backgrounds of the study
population might affect gene expression data. In the present
study, to identify the molecular network of the genes deregu-
lated in MS, we performed microarray analysis of peripheral
blood T cells isolated from the genetically homogeneous popu-
lation of Hungarian MZ MS/MS and MS/healthy subject twins
0304-3940/$ – see front matter © 2007 Elsevier Ireland Ltd. All rights reserved.
doi:10.1016/j.neulet.2007.05.056
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followed by gene network analysis using a novel bioinformatic
tool. We focused highly purified CD3+ T cells because autore-
active pathogenic and regulatory cells might be enriched in this
fraction.
Hungarian MZ MS twins were followed up for 2–15 years
by certified neurologists (ZI and CR) at the MS Clinic of Pecs
and Budapest. After written informed consent was taken, CD3+
T cells were isolated form heparinized peripheral blood of three
pairs of concordant MZ MS twins (Families #l to #3) and a
pair of discordant MZ MS/healthy subject twin (Family #4), as
described previously [6,16,15]. All subjects are women with the
mean age of 33± 5 years and the mean disease duration of 6± 5
years. MS was diagnosed following the established criteria [8].
The patients were clinically active, showed variable lesion dis-
tributions on MRI, and exhibited a typical relapsing-remitting
clinical course, except for one patient in Family #3 with clin-
ically isolated syndrome (CIS). The patients showed the mean
Expanded Disability Status Scale (EDSS) score of 1.3± 0.8.
The clinical profile of the patients is shown in Supplementary
Table 1 online. To minimize the influence of confounding fac-
tors on gene expression, none of the patients have received
corticosteroids, interferons, glatiramer acetate, mitoxantrone or
other immunosuppresive medications at least for 8 weeks before
blood sampling. The present study was approved by the ethics
committee of all institutes involved.
We utilized a custom microarray containing duplicate cDNA
spots of 1258 well annotated genes of various functional
classes, including cytokines/growth factors and their recep-
tors, apoptosis regulators, oncogenes, transcription factors,
signal transducers, cell cycle regulators and housekeeping genes
(Hitachi Life Science, Saitama, Japan) [6,16,15]. Five micro-
grams of total RNA isolated fromCD3+ T cells by using RNeasy
Mini Kit (Qiagen, Valencia, CA) was in vitro amplified, and
the antisense RNA (aRNA) was labeled with a fluorescent dye
Cy5, while universal reference aRNA was labeled with Cy3.
The arrays were hybridized at 62 ◦C for 10 h in the hybridization
buffer containing equal amounts of Cy3- or Cy5-labeled cDNA,
and theywere then scanned by the ScanArray 5000 scanner (GSI
Lumonics, Boston, MA). The data were analyzed by using the
QuantArray software (GSI Lumonics). The average of fluores-
cence intensities of duplicate spots was obtained after global
normalization between Cy3 and Cy5 signals.
Because microarray analysis generally produces a large
amount of gene expression data at one time, it is often difficult
to identify the meaningful relationship between gene expres-
sion profile and biological implications from available data.
To overcome this difficulty, we conducted a novel bioinfor-
matic approach to extract the molecular network that is the
most relevant to the microarray data. The molecular network
of the genes identified by microarray was analyzed by using the
software named KeyMolnet originally developed by the Insti-
tute of Medical Molecular Design Inc., Tokyo, Japan (IMMD)
[14]. KeyMolnet constitutes a comprehensive content database,
composed of information on relationships among human genes,
molecules, diseases, pathways and drugs, which have been care-
fully curated from selected review articles, literature, and public
databases by expert biologists of IMMD. The contents are quar-
terly updated, composed of approximately 12,000 molecules in
the version of April 1, 2007, and categorized into either the core
contents collected from selected review articles with the highest
reliability or the secondary contents extracted from abstracts of
the PubMed database.
When DNA microarray data, i.e. the lists of either GenBank
accession number or probe ID, were imported into KeyMolnet,
it automatically provided corresponding molecules as a node
on networks [7,14]. Among four different modes of search, the
common upstream search method enables us to extract the most
relevant molecular network composed of the genes coordinately
regulated by putative common upstream transcription factors.
The generated network was compared side by side with total
346 established canonical pathways of human cells pre-installed
in KeyMolnet. The algorithm counting the number of overlap-
ping molecular relations between the extracted network and the
canonical pathway makes it possible to identify the canoni-
cal pathway showing the most significant contribution to the
extracted network. The significance in the similarity between
both is scored following the formula, where O= the number
of overlapping molecular relations between the extracted net-
work and the canonical pathway, V= the number of molecular
relations located in the extracted network, C= the number of
molecular relations located in the canonical pathway, T= the
number of total molecular relations, composed of approximately
90,000 different sets pre-installed in KeyMolnet (the version of
1 April 2007), and X= the sigma variable that defines incidental
agreement [3].
score = −log2


Min (C,V )
∑
x=O
f (x)


f (x) =
C
C
x
·
T−CCV−x
T
C
V
By microarray analysis, we identified top 50 and 100 differ-
entially expressed genes (DEG) in T cells between eachMS twin
pair numbered #1 to #4 described above. Then, we selected a
panel of 34 genes that were listed in 50 DEG of the discordant
twin (MS/healthy subject) of Family #4 but were not included
in 100 DEG of the concordant (MS/MS) twin pairs of Families
#l to #3. Among the 34 genes, we further extracted a set of 20
DEG by a cut-off point greater or equal to two-fold difference
between the Family #4 pair. Then, to identify the molecular net-
work with the most close relationship with 20 DEG, the gene list
was imported into KeyMolnet (the version of 1 January 2007).
This automatically extracted 43 genes directly linked to 20DEG.
The common upstream search of 43 genes illustrated a complex
molecular network composed of 39 nodes (Fig. 1). By statis-
tical analysis described above, the generated network showed
the most significant relationship with gene regulation by the Ets
transcription factor family presentingwith the score of 10.2. This
was followed by gene regulation by the nuclear factor NF-kB
in the second rank (the score 9.0), the Myc/Mad family in the
third rank (7.0), the IFN-regulatory factor (IRF) family in the
fourth rank (6.0), and the estrogen receptor (ER) family in the
fifth rank (4.7).
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Fig. 1. The common upstream search of 20 differentially expressed genes in T cells of the discordant twin. The microarray data of 20 DEG in T cells differentilally
expressed between the discordant MZ twin pair (Family #4) were imported into KeyMolnet that extracted 43 genes directly linked to 20 DEG. The common upstream
search of 43 genes generated a molecular network composed of 39 nodes arranged according to the subcellular distribution. Red nodes represent upregulated genes,
whereas blue nodes represent downregulated genes in MS. White nodes exhibit the genes automatically settled by KeyMolnet to establish molecular connections.
The direction of molecular relation is indicated by dash line with arrow (transcriptional activation) or dash line with arrow and stop (transcriptional repression). Thick
lines indicate the core contents, while thin lines indicate the secondary contents of KeyMolnet.
The Ets family transcription factor, by interacting with vari-
ous co-regulatory factors, controls the expression of awide range
of target genes essential for cell proliferation, differentiation,
transformation, and apoptosis [18]. Ets-1, the founder member
of the Ets family, is pivotal for survival and differentiation of
T cells [10]. The Ets family transcription factors regulate the
gene expression of autoimmune regulator (AIRE) that directs
the expression of self-antigens in thymus potentially related to
the autoimmune process of MS [9]. The NF-kB family, consist-
ing of NF-kB1 (p50/p105), NF-kB2 (p52/p100), RelA (p65),
RelB, and c-Rel, acts as a central regulator of innate and adaptive
immune responses, cell proliferation, and apoptosis [1]. More
than 150 target genes for NF-kB are currently identified [12].
A significant subset of NF-kB target genes, including proin-
flammatory cytokines TNFa and IL-1b, activate the expression
of NF-kB, providing a positive regulatory loop that amplifies
and perpetuates inflammatory responses [1]. Importantly, RelA,
c-Rel, and p50 are overexpressed in macrophages in active
demyelinating lesions of MS [4]. Furthermore, RelA expression
is enhanced on oligodendrocytes that survive in the lesion edge
[2]. Recently, we found that the expression of the orphan nuclear
receptor NR4A2, a direct target gene of NF-kB, is elevated
at the highest level in CD3+ T cells of untreated MS patients
[16,15]. Furthermore, targeted disruption of the NFKB1 gene
confers resistance to development of experimental autoimmune
encephalomyelitis (EAE), an animal model of MS [5]. In vivo
administration of selective inhibitors of NF-kB activation pro-
tects mice from EAE [11]. All of these observations suggest the
principal involvement of aberrant regulation of NF-kB in the
pathogenesis of MS.
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We have recently identified 286 genes differentially
expressed in purified CD3+ T cells between 72 untreated
JapaneseMS patients and 22 age- and sex-matched healthy sub-
jects of heterogeneous genetic backgrounds [16]. When the list
of 286 DEG was imported into KeyMolnet (the version of 1
April 2007), it extracted 456 genes directly linked to 286 DEG.
The common upstream search of 456 genes illustrated a complex
molecular network composed of 335 nodes (Supplementary Fig.
1 online). The generated network showed the most significant
relationshipwith gene regulation byNF-kB (the score 13.0), IRF
(12.3), LRH-1 (12.0), BLIMP-1 (11.4), and Ets (7.4) transcrip-
tion factor families. Thus, these observations suggested again
the central role of aberrant transcriptional regulatory network
that involves NF-kB, Ets, IRF and other transcription factors in
development of pathogenic T cells in the genetically heteroge-
neous population of Japanese MS patients.
Although the sample size in the present study is fairly
small because of limited availability of the samples of MZ MS
twins, the novel bioinformatic approach proposes the logical
hypothesis that aberrant regulation of the complex transcrip-
tional regulatory network might contribute to development of
pathogenicT cells inMS.This hypothesiswarrants evaluation by
using a large cohort of the genetically identical MS and healthy
subject twins.
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V. SUMMARY OF THESES 
1. MAIT and NKT cells are the only known invariant T cells infiltrating brain and 
kidney tumors.  
2. Since NKT cells are present in CNS tumors, their absence in MS plaques is disease-
specific and not related to the CNS environment.  
3. MAIT cells may have a pro-inflammatory subset, which infiltrates tumors. 
4. Brain and kidney tumors differ in infiltrating T cell and MAIT cell subsets: brain 
tumor infiltrating MAIT cells may express additional TCRβ to Vβ2 and Vβ13. 
5. MAIT and NKT cells in tumors do not express CD56 although both CD56
+
 and CD56
- 
subsets are present in the peripheral blood even in patients with cancer. 
6. The percentages of particular innate lymphocytes, Vδ2, NKT-like and NK cells do not 
change in the acute phase of ischemic stroke in contrast to the reported decrease of 
adaptive T cells.  
7. In contrast to unaltered frequency, an acute functional deficiency of innate 
lymphocytes occurs in the acute phase of ischemic stroke, within 6 hours: pro-
inflammatory cytokine production, expression of perforin and NK cytotoxicity are 
decreased, while there is no change in production of Th2 cytokines and Th2-related 
ICOS expression. We may hypothesize that such early deficiency or its disregulated 
normalization may substantially influence susceptibility to infections similarly to 
animal models of cerebral ischemia. 
8. Activation of leukocytes represented by elevation in LAR happens within hours after 
onset of ischemic stroke. 
9. Although LAR was elevated in TIA compared to healthy subjects, it was delayed and 
ameliorated compared to definitive ischemic stroke.
10. Decreased activation of leukocytes reflected by a deficient elevation of LAR may 
predispose to post-stroke infections and predict worse outcome.  
11. Concept about uniformly harmful post-ischemic role of leukocytes should be changed 
and dissected: recruitment of leukocytes to the ischemic brain may be damaging by 
amplifying brain injury. However, systemic activation of leukocytes plays an 
important role in preventing post-stroke infections. 
12. A positive correlation exists between LAR and S100β on the 3rd post-stroke day 
indicating a relationship between extent of infarct and innate immune responses.  
76
13. There is no significant effect – if at all – of the CT60*G allele on susceptibility to MS 
compared to other autoimmune diseases. No genotype-dependent expression 
differences in CTLA-4 and ICOS by T cells were found. Taken together, our data, 
together with previously published studies, suggest lack of association of this common 
autoimmune gene with multiple sclerosis.  
14. A genetic association exists between RRMS and the C2370A polymorphism (AA) of 
the IL23R gene: the susceptible genotype provides a two-fold risk for developing MS. 
15. IL23R may represent a novel shared autoimmunity gene.  
16. Aberrant regulation of the complex transcriptional regulatory network contributes to 
the development of pathogenic T cells in MS.  
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